IJMM International Journal of Molecular Medicine 1107-3756 1791-244X D.A. Spandidos 10.3892/ijmm.2018.3943 ijmm-43-01-0057 Articles Identification of 12 novel loci that confer susceptibility to early-onset dyslipidemia YamadaYoshiji12 KatoKimihiko13 OguriMitsutoshi14 HoribeHideki5 FujimakiTetsuo6 YasukochiYoshiki12 TakeuchiIchiro278 SakumaJun289 Department of Human Functional Genomics, Advanced Science Research Promotion Center, Mie University, Tsu, Mie 514-8507 CREST, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012 Department of Internal Medicine, Meitoh Hospital, Nagoya, Aichi 465-0025 Department of Cardiology, Kasugai Municipal Hospital, Kasugai, Aichi 486-8510 Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Gifu 507-8522 Department of Cardiovascular Medicine, Northern Mie Medical Center Inabe General Hospital, Inabe, Mie 511-0428 Department of Computer Science, Nagoya Institute of Technology, Nagoya, Aichi 466-8555 RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027 Computer Science Department, College of Information Science, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan Correspondence to: Professor Yoshiji Yamada, Department of Human Functional Genomics, Advanced Science Research Promotion Center, Mie University, 1577 Kurima-machiya, Tsu, Mie 514-8507, Japan, E-mail: yamada@gene.mie-u.ac.jp 01 2019 19 10 2018 43 1 57 82 26 04 2018 26 09 2018 Copyright: © Yamada et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The circulating concentrations of triglycerides, high density lipoprotein (HDL)-cholesterol, and low density lipoprotein (LDL)-cholesterol have a substantial genetic component, and the heritability of early-onset dyslipidemia might be expected to be higher compared with late-onset forms. In the present study, exome-wide association studies (EWASs) were performed for early-onset hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia, with the aim to identify genetic variants that confer susceptibility to these conditions in the Japanese population. A total of 8,073 individuals aged ≤65 years were enrolled in the study. The EWASs for hypertriglyceridemia (2,664 cases and 5,294 controls), hypo-HDL-cholesterolemia (974 cases and 7,085 controls), and hyper-LDL-cholesterolemia (2,911 cases and 5,111 controls) were performed with Illumina Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip arrays. The association of allele frequencies for 31,198, 31,133, or 31,175 single nucleotide polymorphisms (SNPs) to hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia, respectively, was examined with Fisher’s exact test. To compensate for multiple comparisons of genotypes with each of the three conditions, Bonferroni’s correction was applied for statistical significance of association. The results demonstrated that 25, 28 and 65 SNPs were significantly associated with hypertriglyceridemia, hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia, respectively. Multivariable logistic regression analysis with adjustment for age and sex revealed that all 25, 28 and 65 of these SNPs were significantly associated with hypertriglyceridemia, hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia, respectively. Following examination of the association of the identified SNPs to serum concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol, linkage disequilibrium of the SNPs, and results of previous genome-wide association studies, we newly identified chromosomal region 19p12 as a susceptibility locus for hypertriglyceridemia, eight loci (MOB3C-TMOD4, LPGAT1, EHD3, COL6A3, ZNF860-CACNA1D, COL6A5, DCLRE1C, ZNF77) for hypo-HDL-cholesterolemia, and three loci (KIAA0319-FAM65B, UBD, LOC105375015) for hyper-LDL-cholesterolemia. The present study thus identified 12 novel loci that may confer susceptibility to early-onset dyslipidemia. Determination of genotypes for the SNPs at these loci may prove informative for assessment of genetic risk for hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia in the Japanese population.

 dyslipidemia hypercholesterolemia hypertriglyceridemia genetics exome-wide association study Introduction

Dyslipidemia, including hypertriglyceridemia, hypo-high density lipoprotein (HDL)-cholesterolemia and hyper-low density lipoprotein (LDL)-cholesterolemia, has a substantial genetic component (1-3). Familial hypercholesterolemia is an autosomal dominant disorder characterized by pronounced increases in the circulating concentrations of total cholesterol and LDL-cholesterol (1,2). One of the underlying causes of familial hypercholesterolemia is a defect in the LDL receptor that is responsible for the uptake of most circulating LDL-cholesterol by the liver (2,4). In addition to mutations of the LDL receptor gene (LDLR), familial hypercholesterolemia can be caused by mutations in the apolipoprotein B gene (APOB), proprotein convertase subtilisin/kexin type 9 gene (PCSK9), cytochrome P450 family 7 subfamily A member 1 gene (CYP7A1), and LDL receptor adaptor protein 1 gene (LDLRAP1) (2,4). Common forms of dyslipidemia are multifactorial and polygenic disorders, that result from an interaction between genetic background and both lifestyle and environmental factors, such as consumption of high-fat or high-calorie diets and physical inactivity (1,5). The heritability of plasma concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol was demonstrated to be 33-43, 40-74, and 41-59%, respectively (6-8). Given that dyslipidemia is a key risk factor for coronary artery disease and ischemic stroke (9,10), as well as for colorectal cancer (11,12), personalized prevention is an important public health goal.

Genome-wide association studies (GWASs) and gene-centric meta-analyses have implicated various genes and loci as determinants of blood lipid levels or of predisposition to dyslipidemia in European-ancestry populations (13-17). Genetic variants associated with lipid profiles have been extensively investigated, with one recent study having identified 157 such loci, including 62 variants not previously reported (18). Recent GWASs (19,20) or studies based on whole-exome (21) or whole-genome (22) sequencing in European-ancestry populations have also identified low-frequency or rare variants associated with circulating lipid levels. A more recent exome-wide association study (EWAS) identified 444 independent variants at 250 loci as being significantly associated with plasma levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, or triglycerides (23). An electronic health record-based study reported that genetic risk scores for circulating LDL-cholesterol and triglyceride levels based on 477 single nucleotide polymorphisms (SNPs) were predictive of age at initiation of treatment with lipid-lowering medication (24). Although various SNPs have been demonstrated to be associated with blood lipid profiles in East Asian (25,26) or Japanese (27) populations, genetic variants that contribute to susceptibility to dyslipidemia in Japanese remain to be identified definitively.

Given the substantial genetic component of the circulating concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol (6-8), the genetic contribution to early-onset forms of hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia may be greater compared with late-onset forms (2,3). The statistical power of genetic association studies may thus be increased by focusing on subjects with early-onset forms of these disorders.

The present study performed EWASs for early-onset forms of hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia with the use of human exome array-based genotyping methods. The aim was to identify genetic variants that confer susceptibility to these conditions in the Japanese population.

 Materials and methods Study subjects

In our previous studies, the median age of subjects with hypertriglyceridemia, hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia was 64, 68 or 62 years, respectively (28). Therefore, in the present study, early-onset dyslipidemia was defined as that occurring at an age of ≤65 years. A total of 8,073 individuals aged ≤65 years were examined. Recruited subjects either visited outpatient clinics or were admitted to participating hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Northern Mie Medical Center Inabe General Hospital, Inabe; Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki) because of various symptoms or for an annual health checkup between 2002 and 2014, or were community-dwelling individuals recruited to a population-based cohort study in Inabe between 2010 and 2014 (29).

Venous blood was collected in the early morning after subjects had fasted overnight. The blood samples were centrifuged at 1,600 x g for 15 min at 4°C, and serum was separated for subsequent analysis. Serum concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol were measured in the clinical laboratory of each hospital. The 2,664 subjects with hypertriglyceridemia and 5,294 controls had serum triglyceride concentrations of ≥1.69 mmol/l (150 mg/dl) and <1.69 mmol/l, respectively. The 974 subjects with hypo-HDL-cholesterolemia and 7,085 controls had serum HDL-cholesterol concentrations of <1.03 mmol/l (40 mg/dl) and ≥1.03 mmol/l, respectively. The 2,911 subjects with hyper-LDL-cholesterolemia and 5,111 controls had serum LDL-cholesterol concentrations of ≥3.62 mmol/l (140 mg/dl) and <3.62 mmol/l, respectively. The 562 subjects with both hypertriglyceridemia and hypo-HDL-cholesterolemia, and the 4,907 controls, overlapped between the corresponding studies, as did the 1,312 subjects with both hypertriglyceridemia and hyper-LDL-cholesterolemia and 3,723 controls, as well as the 317 subjects with both hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia and 4,484 controls. Individuals with single-gene disorders, such as familial hypercholesterolemia, or with endocrinologic or metabolic diseases that cause dyslipidemia were excluded from the study. Those taking medications that may cause secondary dyslipidemia were also excluded.

 EWAS

Venous blood was collected into tubes containing 50 mmol/l EDTA (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells with the use of a kit (Genomix, Talent Srl, Trieste, Italy; or SMITEST EX-R&D, Medical & Biological Laboratories, Co., Ltd., Nagoya, Japan). EWASs for hypertriglyceridemia (2,664 cases and 5,294 controls), hypo-HDL-cholesterolemia (974 cases and 7,085 controls), and hyper-LDL-cholesterolemia (2,911 cases and 5,111 controls) were performed with Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip arrays (Illumina, San Diego, CA, USA). These exome arrays include putative functional exonic variants selected from ~12,000 individual exome and whole-genome sequences. The exonic content consists of ~244,000 SNPs from diverse populations, including European, African, Chinese, and Hispanic individuals (30). SNPs contained in only one of the arrays (~2.6% of all SNPs) were excluded from analysis. Quality control was performed, as previously described (31). Briefly, genotyping data with a call rate of <97% were discarded, with the mean call rate for the remaining data being 99.9%. Gender specification was checked for all samples, and those for which gender phenotype in the clinical records was inconsistent with genetic sex were discarded. Duplicated samples and cryptic relatedness were checked by calculation of identity by descent; all pairs with a value of >0.1875 were inspected and one sample from each pair was excluded. Heterozygosity of SNPs was calculated for all samples, and those with extremely low or high heterozygosity (>3 standard deviations from the mean) were discarded. SNPs in sex chromosomes or mitochondrial DNA were excluded from analysis, as were non-polymorphic SNPs or SNPs with a minor allele frequency of <1.0%. SNPs whose genotype distributions deviated significantly (P<0.01) from Hardy-Weinberg equilibrium in control individuals were discarded. Finally, genotype data for each EWAS were examined for population stratification by principal components analysis (32), and population outliers were excluded from further study. A total of 31,198, 31,133, and 31,175 SNPs passed quality control in the EWASs for hypertriglyceridemia, hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia, respectively, and were subjected to further analyses.

 Statistical analysis

For analysis of characteristics of the study subjects, quantitative and categorical data were compared between cases and controls with the unpaired Student’s t-test and Pearson’s Chi-square test, respectively. Allele frequencies were estimated by the gene counting method, and departure from Hardy-Weinberg equilibrium was identified with Fisher’s exact test. The association of allele frequencies of SNPs to hypertriglyceridemia, hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia in the EWASs was examined with Fisher’s exact test. To compensate for multiple comparisons of allele frequencies with hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia, Bonferroni’s correction was applied for statistical significance of association. Given that 31,198, 31,133 or 31,175 SNPs were analyzed, a P-value of <1.60×10−6 [0.05/(31,198 or 31,175)] for hypertriglyceridemia and hyper-LDL-cholesterolemia and a P-value of <1.61×10−6 (0.05/31,133) for hypo-HDL-cholesterolemia was considered statistically significant for association. The inflation factor (λ) was 1.07 for hypertriglyceridemia, 1.05 for hypo-HDL-cholesterolemia, and 1.00 for hyper-LDL-cholesterolemia. Multivariable logistic regression analysis was performed with hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia as a dependent variable and independent variables including age, sex (0, woman; 1, man), and genotype of each SNP. Genotypes of SNPs were assessed according to dominant [0, AA; 1, AB + BB (A, major allele; B, minor allele)], recessive (0, AA + AB; 1, BB), and additive genetic models, and the P-value, odds ratio, and 95% confidence interval were calculated. Additive models comprised additive 1 (0, AA; 1, AB; 0, BB) and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which were analyzed simultaneously with a single statistical model. Associations of genotypes of identified SNPs to serum concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol were examined by one-way analysis of variance. Bonferroni’s correction was also applied to other statistical analysis as indicated. Statistical tests were performed with JMP Genomics version 9.0 software (SAS Institute, Cary, NC, USA).

 Results Characteristics of subjects

The characteristics of the 7,958 subjects enrolled in the hypertriglyceridemia study are listed in Table I. Age, the frequency of men, and the prevalence of smoking, obesity, hypertension, diabetes mellitus, chronic kidney disease, and hyperuricemia as well as body mass index (BMI), systolic and diastolic blood pressure (BP), fasting plasma glucose (FPG) level, blood glycosylated hemoglobin (hemoglobin A1c) content, and serum concentrations of creatinine and uric acid were greater, whereas the serum concentration of HDL-cholesterol and estimated glomerular filtration rate (eGFR) were lower, in subjects with hypertriglyceridemia compared with controls.

The characteristics of the 8,059 subjects enrolled in the hypo-HDL-cholesterolemia study are listed in Table II. Age, the frequency of men, and the prevalence of smoking, obesity, hypertension, diabetes mellitus, chronic kidney disease, and hyperuricemia as well as BMI, systolic and diastolic BP, FPG level, blood hemoglobin A1c content, and serum concentrations of triglycerides, creatinine, and uric acid were greater, whereas eGFR was lower, in subjects with hypo-HDL-cholesterolemia compared with controls.

The characteristics of the 8,022 subjects enrolled in the hyper-LDL-cholesterolemia study are listed in Table III. Age, the prevalence of obesity, BMI, diastolic BP, and serum concentrations of triglycerides and uric acid were greater, whereas systolic BP and serum concentrations of HDL-cholesterol and creatinine were lower, in subjects with hyper-LDL-cholesterolemia compared with controls.

 EWASs for hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia

The association of allele frequencies for 31,198 SNPs that passed quality control to hyper-triglyceridemia was examined with the use of Fisher’s exact test. Following Bonferroni’s correction, 25 SNPs were significantly associated with hypertriglyceridemia (P<1.60×10−6; Table IV). Similar analysis of the association of allele frequencies for 31,133 SNPs to hypo-HDL-cholesterolemia or of those for 31,175 SNPs to hyper-LDL-cholesterolemia revealed that 28 SNPs were significantly associated with hypo-HDL-cholesterolemia (P<1.61×10−6; Table V) and 65 SNPs with hyper-LDL-cholesterolemia (P<1.60×10−6; Table VI).

 Multivariable logistic regression analysis of the association of SNPs to hypertriglyceridemia, hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia

The association of the 25 SNPs identified in the EWAS for hypertriglyceridemia to this condition was further examined by multivariable logistic regression analysis, following adjustment for age and sex. All 25 SNPs were significantly [P<0.0005 (0.05/100) in at least one genetic model] associated with hypertriglyc-eridemia (Table VII). Similar analysis revealed that all 28 SNPs identified in the EWAS for hypo-HDL-cholesterolemia [P<0.0004 (0.05/112); Table VIII] and all 65 SNPs identified in the EWAS for hyper-LDL-cholesterolemia [P<0.0002 (0.05/260); Table IX] were significantly associated with the respective conditions.

 Association of identified SNPs to serum concentrations of triglycerides, HDL-cholesterol or LDL-cholesterol

The association of the genotypes of identified SNPs to serum concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol was examined by one-way analysis of variance. The 25 SNPs identified in the EWAS for hypertriglyceridemia were all significantly associated with serum triglyceride concentration [P<0.0020 (0.05/25); Table X]. Among the 28 SNPs identified in the EWAS for hypo-HDL-cholesterolemia, 27 polymorphisms were significantly associated with the serum HDL-cholesterol level [P<0.0018 (0.05/28)], whereas rs114501427 of SPOPL was not related to this parameter (Table XI). Among the 65 SNPs identified in the EWAS for hyper-LDL-cholesterolemia, 37 SNPs were significantly associated with serum LDL-cholesterol concentration [P<0.0008 (0.05/65); Table XII]. It is possible that the lack of significant correlation between the remaining 28 SNPs and the serum LDL-cholesterol levels may be due to effects of medical treatment.

 Linkage disequilibrium analysis

The linkage disequilibrium (LD) was assessed among SNPs associated with hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia. For the hypertriglyceridemia study, strong LD was apparent among rs1260326 and rs780093 of GCKR and rs1260333 at chromosome 2p23 [square of the correlation coefficient (r2), 0.876-0.983]. An LD plot for the 12 SNPs located at chromosomal region 8p21.3 is illustrated in Fig. 1. Strong LD was observed among rs301, rs326, rs13702, and rs15285 of LPL, rs2083637 and rs1441756 (r2, 0.942-0.988), as well as among rs328 of LPL, rs10096633, rs17482753, rs12678919, rs10503669 and rs7016880 (r2, 0.910-0.999). An LD plot for the eight SNPs located at chromosomal region 11q23.3 is illustrated in Fig. 2. Significant LD was apparent among rs10790162 of BUD13, rs7350481, rs9326246, both rs964184 and rs2075290 of ZPR1, and rs2266788 of APOA5 (r2, 0.687-0.990).

For the hypo-HDL-cholesterolemia study, significant LD was apparent between rs139537100 of MOB3C and rs115287176 of TMOD4 (r2, 0.984); between rs116417209 of EHD3 and rs114501427 of SPOPL (r2, 0.703); between rs140232911 of ZNF860 and rs35874056 of CACNA1D (r2, 1.00); among rs192210727 of ADGRL3, rs188378669 of CXCL8, and rs61734696 of MARCH1 (r2, 0.901 to 0.972); between rs199921354 of VPS33B and rs141569282 of OR4F6 (r2, 0.994); and between rs247616 and rs3764261 at chromosome 16q13 (r2, 0.992). An LD plot for the five SNPs located at chromosomal region 12q24.12 to 12q24.13 is illustrated in Fig. 3. Significant LD was detected among rs3782886 of BRAP, rs11066015 of ACAD10, rs671 of ALDH2, and rs2074356 and rs11066280 of HECTD4 (r2, 0.813-0.995).

For the hyper-LDL-cholesterolemia study, significant LD was apparent among rs147284320 of PTCH2, rs139537100 of MOB3C and rs115287176 of TMOD4 (r2, 0.828-0.984); among rs192210727 of ADGRL3, rs188378669 of CXCL8, and rs61734696 of MARCH1 (r2, 0.901-0.972); and between rs200787930 of PLCB2 and rs199921354 of VPS33B (r2, 0.994). An LD plot for the 47 SNPs located at chromosomal region 6p22.3 to 6p21.3 is illustrated in Fig. 4. There were two major LD blocks. The first LD block (r2, 0.571-1.000) comprised rs7749235, rs2285321, and rs6937357 of DHX16; rs9468805, rs6457254, and rs2394392 of PPP1R18; rs3130663 at 6p21.3; rs2269702, rs28986465, rs2075015, and rs6924270 of MDC1; and rs3132584, rs25527, and rs9500864 of TUBB. The second LD block (r2, 0.762-1.000) comprised rs147733073 of CCHCR1; rs2596574 at 6p21.3; rs11538264 of PRRC2A; rs9267546, rs17200983, and rs9267547 of LY6G6F; rs117894946 of LY6G6C; rs11754464 of MSH5; rs5030798 and rs11751198 of VARS; rs6457452 of HSPA1B; rs11968400 of C6orf48; rs12210887 at 6p21.3; rs13118 of NEU1; rs117127493 of SLC44A4; rs492899 of SKIV2L; rs140770834 and rs11751545 of TNXB; and rs204999 at 6p21.3. Significant LD was also observed between rs4576240 of KIAA0319 and rs150142878 of FAM65B (r2, 0.893); among rs34902660 of SLC17A3, rs76463649 of ZSCAN26, rs6922302 of ZSCAN31, rs29243 of GABBR1, and rs2523995 of TRIM40 (r2, 0.601-0.995); between rs64036 of UBD and rs2524272 at 6p22.1 (r2, 0.753); and among rs6933400 and rs11970154 of DPCR1, rs2508015 at 6p21.3, and rs147733073 of CCHCR1 (r2, 0.596-0.987).

 Relation of SNPs identified in the present study to dyslipidemia-related phenotypes examined in previous GWASs

The relation of genes, chromosomal loci and SNPs identified in the present study was further analyzed against phenotypes previously examined by GWASs available in the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search v.2.0.0.0 (https://grasp.nhlbi.nih.gov/Search.aspx) developed by the Information Technology and Applications Center, National Center for Biotechnology Information, National Heart, Lung, and Blood Institute, National Institutes of Health (Bethesda, MD, USA) (33,34).

In the hypertriglyceridemia study, GCKR, chromosomal region 2p23, LPL, region 8p21.3, region 8q24.2, BUD13, region 11q23.3, ZPR1, APOA5, and APOA4 have been previously reported to be associated with circulating triglyceride concentrations, whereas chromosome 19p12 had not been related to triglyceride levels or other dyslipidemia-related traits (Table XIII).

In the study of hypo-HDL-cholesterolemia, APOA5, BRAP, ALDH2, HECTD4, chromosome 16q13, CETP, and LILRB2 were previously reported to be associated with circulating HDL-cholesterol levels, whereas CXCL8, ACAD10, and PLCB2 were associated with circulating levels of total cholesterol, LDL-cholesterol, and triglycerides, respectively (Table XIV). MARCH1, chromosome 6p22.1, and VPS33B were also associated with adiponectin concentrations, type 1 diabetes mellitus, and type 2 diabetes mellitus, respectively. The remaining 13 genes (MOB3C, TMOD4, LPGAT1, EHD3, SPOPL, COL6A3, ZNF860, CACNA1D, COL6A5, ADGRL3, DCLRE1C, OR4F6, ZNF77) had not been related to circulating HDL-cholesterol or other dyslipidemia-related phenotypes.

In the study of hyper-LDL-cholesterolemia, PCSK9, APOB, chromosome 6p21.3, SKIV2L, HECTD4, APOE, and APOC1 were previously reported to be associated with circulating LDL-cholesterol levels, whereas CXCL8, 6p21.3, CCHCR1, PRRC2A, LY6G6F, MSH5, C6orf48, SLC44A4, TNXB, and PLCB2 were associated with circulating concentrations of total cholesterol or triglycerides (Table XV). MARCH1, SLC17A3, ZSCAN31, GABBR1, 6p22.1, TRIM40, PPP1R18, 6p21.3, MDC1, TUBB, DPCR1, LY6G6C, VARS, HSPA1B, and VPS33B were associated with diabetes mellitus-associated phenotypes. The remaining 16 genes (PTCH2, MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, KIAA0319, FAM65B, ZSCAN26, UBD, DHX16, LOC105375015, NEU1, MUC17, GIT2, ZNF77) had not been related to circulating LDL-cholesterol or other dyslipidemia-related phenotypes.

 Network analysis of genes identified in the present study

Network analysis of the 10 genes (MOB3C, TMOD4, LPGAT1, EHD3, COL6A3, ZNF860, CACNA1D, COL6A5, DCLRE1C, ZNF77) or three genes (KIAA0319, FAM65B, UBD) associated in the present study with hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia, respectively, was performed to predict functional gene-gene interactions, with the use of the GeneMANIA Cytoscape plugin (http://apps.cytoscape.org/apps/genemania; Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Canada) (35-37) and Cytoscape v3.4.0 software (http://www.cytoscape.org; The Cytoscape Consortium, San Diego, CA, USA) (38). Given that LOC105375015 protein has not been characterized, it was not examined. A set of 50 dyslipidemia-related genes were selected from the DisGeNET database (http://www.disgenet.org/web/DisGeNET; Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Barcelona Biomedical Research Park, Barcelona, Spain) (39,40) according to the rank order (high to low) of scores for association with dyslipidemia. The network analysis revealed that the 10 or three genes associated in the present study with hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia, respectively, have potential direct or indirect interactions with the 50 genes previously demonstrated to be associated with dyslipidemia (Fig. 5).

 Discussion

Dyslipidemia is an important public health problem because of its high prevalence and role as a risk factor for more serious conditions, including coronary artery disease, ischemic stroke, and colorectal cancer (9-12). The identification of genetic variants that confer susceptibility to dyslipidemia is thus clinically important for prevention of these conditions. The present study has performed novel EWASs for hypertriglyceridemia, hypo-HDL-cholesterolemia, and hyper-LDL-cholesterolemia in subjects with early-onset forms of these disorders, which may have a greater genetic component compared with late-onset forms.

Among 25 SNPs in six genes and five chromosomal loci significantly associated with early-onset hypertriglyceridemia, the present study newly identified rs11085421 at 19p12 as a susceptibility locus for this condition. This SNP was significantly associated with serum triglyceride concentration, with the minor C allele being protective against hypertriglyceridemia.

Among 28 SNPs in 24 genes and two chromosomal loci significantly associated with hypo-HDL-cholesterolemia, the current study newly identified 13 genes (MOB3C, TMOD4, LPGAT1, EHD3, SPOPL, COL6A3, ZNF860, CACNA1D, COL6A5, ADGRL3, DCLRE1C, OR4F6, ZNF77) as potential susceptibility loci for this condition. SNPs of 12 of these genes were significantly associated with serum HDL-cholesterol levels, with minor alleles of LPGAT1, EHD3, ZNF860, CACNA1D, and DCLRE1C representing risk factors for hypo-HDL-cholesterolemia and minor alleles of MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, OR4F6, and ZNF77 being protective against this condition. Given that rs114501427 of SPOPL was not significantly related to serum HDL-cholesterol concentration, this gene was excluded as a novel susceptibility locus. Furthermore, given that significant LD was apparent among SNPs of ADGRL3, CXCL8, and MARCH1, as well as between SNPs of OR4F6 and VPS33B, ADGRL3 and OR4F6 were also removed from the final list of novel significant loci. In addition, significant LD was detected between SNPs of MOB3C and TMOD4 as well as between those of ZNF860 and CACNA1D. We thus identified eight novel loci (MOB3C-TMOD4, LPGAT1, EHD3, COL6A3, ZNF860-CACNA1D, COL6A5, DCLRE1C, ZNF77) that confer susceptibility to early-onset hypo-HDL-cholesterolemia.

Among 65 SNPs in 44 genes and two chromosomal loci significantly associated with hyper-LDL-cholesterolemia, the present study newly identified 16 genes (PTCH2, MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, KIAA0319, FAM65B, ZSCAN26, UBD, DHX16, LOC105375015, NEU1, MUC17, GIT2, ZNF77) as potential susceptibility loci for this condition. SNPs of six of these genes (KIAA0319, FAM65B, ZSCAN26, UBD, LOC105375015, NEU1) were significantly associated with serum LDL-cholesterol levels, with minor alleles of these genes representing risk factors for hyper-LDL-cholesterolemia. Given that SNPs of 10 genes (PTCH2, MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, DHX16, MUC17, GIT2, ZNF77) were not significantly related to the serum LDL-cholesterol concentration, these genes were removed from the list of novel susceptibility loci, even though this discrepancy may be attributable to the effects of lipid-lowering medication. Given that rs13118 of NEU1 was in significant LD with rs492899 of SKIV2L in a large LD block and that rs76463649 of ZSCAN26 was in LD with SNPs of SLC17A3, ZSCAN31, GABBR1, and TRIM40, both NEU1 and ZSCAN26 were also excluded from the final results. In addition, significant LD was detected between SNPs of KIAA0319 and FAM65B. We thus identified three novel loci (KIAA0319-FAM65B, UBD, LOC105375015) that confer susceptibility to early-onset hyper-LDL-cholesterolemia.

A recent study has reported that network analysis of functional gene-gene interactions may be informative with regard both to clarification of biological processes underlying coronary artery disease and to the identification of therapeutic targets for this condition (41). A network analysis was therefore performed in the present study in order to predict biological processes related to the identified genes and the interactions of these genes with those previously known to be associated with dyslipidemia. The results from the network analysis revealed that the 10 or three genes associated in the present study with hypo-HDL-cholesterolemia or hyper-LDL-cholesterolemia respectively, had direct or indirect interactions with the 50 dyslipidemia-related genes selected from the DisGeNET database (39,40). The underlying molecular mechanisms of these interactions, however, remain to be elucidated.

Our group has previously reported that two, three and nine SNPs were associated with hypertriglyceridemia (P<1.71×10−4), hypo-HDL-cholesterolemia (P<1.44×10−4), and hyper-LDL-cholesterolemia (P<1.10×10−4), respectively, as determined by multivariable logistic regression analysis with adjustment for age and sex, following an initial EWAS screening of allele frequencies among subjects with early- or late-onset forms of these conditions (28). The associations of the two SNPs [rs10790162 (P=3.58×10−24) and rs7350481 (P=7.94×10−23)] with hypertriglyceridemia were replicated (P<0.05) in the present study. The associations of two of the three SNPs [rs147317864 (P=0.0139) and rs12229654 (P= 0.0001)] with hypo-HDL-cholesterolemia were replicated in the present study. The associations of eight of the nine SNPs [rs7771335 (P=1.00×10−7), rs2071653 (P=1.61×10−5), rs2853969 (P= 6.16×10−8), rs2269704 (P=2.92×10−7), rs2269703 (P=3.67×10 −7), rs495089 (P= 0.0 0 01), rs2269702 (P=5.13×10−7) and rs1233399 (P=0.0009)] with hyper-LDL-cholesterolemia were replicated in the present study. Although the association of most SNPs with dyslipidemia identified in our previous study (28) was replicated, genetic variants associated with hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia appear to differ, at least in part, between early- and late-onset forms of the diseases.

There are several limitations to the present study. Firstly, given that the results were not replicated, their validation will be necessary in independent study populations or in other ethnic groups. The identified SNPs were not tested in a clinical setting to validate the assessment of genetic risk for dyslipidemia in patients. In addition, it is possible that SNPs identified in the present study may be in LD with other genetic variants in the same gene or in nearby genes that are actually responsible for the development of hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia. Finally, the functional relevance of identified SNPs to the pathogenesis of hypertriglyceridemia, hypo-HDL-cholesterolemia, or hyper-LDL-cholesterolemia remains to be elucidated.

In conclusion, the present study has identified chromosome 19p12, eight loci (MOB3C-TMOD4, LPGAT1, EHD3, COL6A3, ZNF860-CACNA1D, COL6A5, DCLRE1C, ZNF77) and three loci (KIAA0319-FAM65B, UBD, LOC105375015) that confer susceptibility to early-onset hypertriglyceridemia, hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia, respectively. Determination of genotypes for the SNPs at these loci may prove informative for assessment of genetic risk for hypertriglyceridemia, hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia in the Japanese population.

 Acknowledgments

Not applicable.

 Funding

This work was supported by CREST, Japan Science and Technology Agency (grant no. JPMJCR1302; to YYam, JS and IT).

 Availability of data and materials

All data underlying the findings described in the article are available on request from the corresponding author.

 Authors’ contributions

YYam contributed to conception and design of the study; to acquisition, analysis, and interpretation of the data; and to drafting of the manuscript. KK, MO, HH, and TF each contributed to acquisition of the data and to revision of the manuscript. YYas, IT, and JS contributed to analysis and interpretation of the data as well as to revision of the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The study protocol complied with the Declaration of Helsinki and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine, Hirosaki University Graduate School of Medicine, and participating hospitals (Gifu Prefectural Tajimi Hospital, Gifu Prefectural General Medical Center, Japanese Red Cross Nagoya First Hospital, Northern Mie Medical Center Inabe General Hospital, and Hirosaki Stroke and Rehabilitation Center). Written informed consent for participation in the study was obtained from all subjects.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References DurringtonPDyslipidaemiaLancet362717731200310.1016/S0140-6736(03)14234-112957096 PaththinigeCSSirisenaNDDissanayakeVGenetic determinants of inherited susceptibility to hypercholesterolemia-a comprehensive literature reviewLipids Health Dis16103201710.1186/s12944-017-0488-4 DronJSHegeleRAGenetics of triglycerides and the risk of atherosclerosisCurr Atheroscler Rep1931201710.1007/s11883-017-0667-9285341275440481 SoutarAKNaoumovaRPMechanism of disease: Genetic causes of familial hypercholesterolemiaNat Clin Pract Cardiovasc Med4214225200710.1038/ncpcardio083617380167 HellerDADeFaireUPedersenNDahlénGMcClearnGEGenetic and environmental influences on serum lipid levels in twinsN Engl J Med32811501156199310.1056/NEJM1993042232816038455681 AbneyMMcPeekMSOberCBroad and narrow herita-bilities of quantitative traits in a founder populationAm J Hum Genet6813021307200110.1086/320112113096901226113 van DongenJWillemsenGChenWMde GeusEJBoomsmaDIHeritability of metabolic syndrome traits in a large population-based sampleJ Lipid Res5429142923201310.1194/jlr.P041673239180463770104 WooJGMorrisonJAStroopDMAronson FriedmanLMartinLJGenetic architecture of lipid traits changes over time and differs by race: Princeton Lipid Follow-up StudyJ Lipid Res5515151524201410.1194/jlr.M049932248597844076086 BenjaminEJViraniSSCallawayCWChamberlainAMChangARChengSChiuveSECushmanMDellingFNDeoRHeart disease and stroke statistics-2018 update: A report from the American Heart AssociationCirculation137e67e492201810.1161/CIR.000000000000055829386200 LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysisBr Med J3261423200310.1136/bmj.326.7404.1423 AgnoliCGrioniSSieriSSacerdoteCVineisPTuminoRGiurdanellaMCPalaVMattielloAChiodiniPColorectal cancer risk and dyslipidemia: A case-cohort study nested in an Italian multicentre cohortCancer Epidemiol38144151201410.1016/j.canep.2014.02.00224636241 YaoXTianZDyslipidemia and colorectal cancer risk: A meta-analysis of prospective studiesCancer Causes Control26257268201510.1007/s10552-014-0507-y KathiresanSMelanderOGuiducciCSurtiABurttNPRiederMJCooperGMRoosCVoightBFHavulinnaASSix new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humansNat Genet40189197200810.1038/ng.75181930442682493 KathiresanSWillerCJPelosoGMDemissieSMusunuruKSchadtEEKaplanLBennettDLiYTanakaTCommon variants at 30 loci contribute to polygenic dyslipidemiaNat Genet415665200910.1038/ng.291 AulchenkoYSRipattiSLindqvistIBoomsmaDHeidIMPramstallerPPPenninxBWJanssensACWilsonJFSpectorTLoci influencing lipid levels and coronary heart disease risk in 16 European population cohortsNat Genet414755200910.1038/ng.2692687074 TeslovichTMMusunuruKSmithAVEdmondsonACStylianouIMKosekiMPirruccelloJPRipattiSChasmanDIWillerCJBiological, clinical and population relevance of 95 loci for blood lipidsNature466707713201010.1038/nature09270206865653039276 AsselbergsFWGuoYvan IperenEPSivapalaratnamSTraganteVLanktreeMBLangeLAAlmogueraBAppelmanYEBarnardJLarge-scale gene-centric meta-analysis across 32 studies identifies multiple lipid lociAm J Hum Genet91823838201210.1016/j.ajhg.2012.08.032230636223487124 WillerCJSchmidtEMSenguptaSPelosoGMGustafssonSKanoniSGannaAChenJBuchkovichMLMoraSDiscovery and refinement of loci associated with lipid levelsNat Genet4512741283201310.1038/ng.2797240970683838666 PelosoGMAuerPLBisJCVoormanAMorrisonACStitzielNOBrodyJAKhetarpalSACrosbyJRFornageMAssociation of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacksAm J Hum Genet94223232201410.1016/j.ajhg.2014.01.009245077743928662 SurakkaIHorikoshiMMägiRSarinAPMahajanALagouVMarulloLFerreiraTMiraglioBTimonenSThe impact of low-frequency and rare variants on lipid levelsNat Genet47589597201510.1038/ng.3300259619434757735 LangeLAHuYZhangHXueCSchmidtEMTangZZBizonCLangeEMSmithJDTurnerEHWhole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterolAm J Hum Genet94233245201410.1016/j.ajhg.2014.01.010245077753928660 HelgadottirAGretarsdottirSThorleifssonGHjartarsonESigurdssonAMagnusdottirAJonasdottirAKristjanssonHSulemPOddssonAVariants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary diseaseNat Genet48634639201610.1038/ng.356127135400 LiuDJPelosoGMYuHButterworthASWangXMahajanASaleheenDEmdinCAlamDAlvesACExome-wide association study of plasma lipids in >300,000 individualsNat Genet4917581766201710.1038/ng.3977290834085709146 HoffmannTJTheuschEHaldarTRanatungaDKJorgensonEMedinaMWKvaleMNKwokPYSchaeferCKraussRMA large electronic-health-record-based genome-wide study of serum lipidsNat Genet50401413201810.1038/s41588-018-0064-5295074225942247 PelosoLu XLiuGMWuDJZhangYZhouHLiWTangJDorajooCSLiRHExome chip meta-analysis identifies novel loci and East Asian-specific coding variants that contribute to lipid levels and coronary artery diseaseNat Genet4917221730201710.1038/ng.3978290834075899829 SpracklenCNChenPKimYJWangXCaiHLiSLongJWuYWangYXTakeuchiFAssociation analyses of East Asian individuals and trans-ancestry analyses with European individuals reveal new loci associated with cholesterol and triglyceride levelsHum Mol Genet2617701784201710.1093/hmg/ddx062283348996075203 KuranoMTsukamotoKKamitsujiSKamataniNHaraMIshikawaTKimBJMoonSJin KimYTeramotoTGenome-wide association study of serum lipids confirms previously reported associations as well as new associations of common SNPs within PCSK7 gene with triglycerideJ Hum Genet61427433201610.1038/jhg.2015.17026763881 YamadaYSakumaJTakeuchiIYasukochiYKatoKOguriMFujimakiTHoribeHMuramatsuMSawabeMIdentification of eight genetic variants as novel determinants of dyslipidemia in Japanese by exome-wide association studiesOncotarget838950389612017284736625503585 YamadaYMatsuiKTakeuchiIOguriMFujimakiTAssociation of genetic variants with hypertension in a longitudinal population-based genetic epidemiological studyInt J Mol Med3511891198201510.3892/ijmm.2015.2151258135344380208 GroveMLYuBCochranBJHarituniansTBisJCTaylorKDHansenMBoreckiIBCupplesLAFornageMBest practices and joint calling of the HumanExome BeadChip: The CHARGE ConsortiumPLoS One8e68095201310.1371/journal.pone.0068095238745083709915 AndersonCAPetterssonFHClarkeGMCardonLRMorrisAPZondervanKTData quality control in genetic case-control association studiesNat Protoc515641573201010.1038/nprot.2010.116210851223025522 PriceALPattersonNJPlengeRMWeinblattMEShadickNAReichDPrincipal components analysis corrects for stratification in genome-wide association studiesNat Genet38904909200610.1038/ng184716862161 LeslieRO’DonnellCJJohnsonADGRASP: Analysis of genotype-phenotype results from 1,390 genome-wide association studies and corresponding open access databaseBioinformatics30i185-i194201410.1093/bioinformatics/btu273 EicherJDLandowskiCStackhouseBSloanAChenWJensenNLienJPLeslieRJohnsonADGRASP v2.0: An update on the genome-wide repository of associations between SNPs and phenotypesNucleic Acids Res43Database IssueD799D804201510.1093/nar/gku12024383982 Warde-FarleyDDonaldsonSLComesOZuberiKBadrawiRChaoPFranzMGrouiosCKaziFLopesCTThe GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene functionNucleic Acids Res38W214W220201010.1093/nar/gkq537205767032896186 MontojoJZuberiKRodriguezHKaziFWrightGDonaldsonSLMorrisQBaderGDGeneMANIA cytoscape plugin: Fast gene function predictions on the desktopBioinformatics2629272928201010.1093/bioinformatics/btq562209264192971582 MontojoJZuberiKRodriguezHBaderGDMorrisQGeneMANIA: Fast gene network construction and function prediction for CytoscapeF1000Res31532014252541044168749 ShannonPMarkielAOzierOBaligaNSWangJTRamageDAminNSchwikowskiBIdekerTCytoscape: A software environment for integrated models of biomolecular interaction networksGenome Res1324982504200310.1101/gr.123930314597658403769 PiñeroJQueralt-RosinachNBravoÀDeu-PonsJBauer-MehrenABaronMSanzFFurlongLIDisGeNET: A discovery platform for the dynamical exploration of human diseases and their genesDatabase (Oxford) 2015bav028201510.1093/database/bav028 PiñeroJBravoÀQueralt-RosinachNGutiérrez-SacristánADeu-PonsJCentenoEGarcía-GarcíaJSanzFFurlongLIDisGeNET: A comprehensive platform integrating information on human disease-associated genes and variantsNucleic Acids Res45D833D839201710.1093/nar/gkw9435210640 LempiäinenHBrænneIMichoelTTraganteVVilneBWebbTRKyriakouTEichnerJZengLWillenborgCNetwork analysis of coronary artery disease risk genes elucidates disease mechanisms and druggable targetsSci Rep83434201810.1038/s41598-018-20721-6294674715821758

LD map for 12 SNPs at chromosomal region 8p21.3 associated with hypertriglyceridemia. LD was calculated as the square of the correlation coefficient (r2), with the extent of LD increasing according to the color order of gray to red. LD, linkage disequilibrium; SNP, single nucleotide polymorphism.

LD map for eight SNPs at chromosomal region 11q23.3 associated with hypertriglyceridemia. LD was calculated as the square of the correlation coefficient (r2), with the extent of LD increasing according to the color order of blue to gray to red. LD, linkage disequilibrium; SNP, single nucleotide polymorphism.

LD map for five SNPs at chromosomal region 12q24.12 to 12q24.13 associated with hypo-HDL-cholesterolemia. LD was calculated as the square of the correlation coefficient (r2), with the extent of LD increasing according to the color order of gray to red. LD, linkage disequilibrium; SNP, single nucleotide polymorphism.

LD map for 47 SNPs at 6p22.3 to 6p21.3 associated with hyper-LDL-cholesterolemia. LD was calculated as the square of the correlation coefficient (r2), with the extent of LD increasing according to the color order of blue to gray to red. LD, linkage disequilibrium; SNP, single nucleotide polymorphism.

Network analysis of the genes identified in the present study with known dyslipidemia-related genes. The 10 genes (MOB3C, TMOD4, LPGAT1, EHD3, COL6A3, ZNF860, CACNA1D, COL6A5, DCLRE1C, ZNF77) and three genes (KIAA0319, FAM65B, UBD) associated in the present study with hypo-HDL-cholesterolemia and hyper-LDL-cholesterolemia, respectively, are indicated in red circles. The 50 dyslipidemia-related genes selected from the DisGeNET database (http://www.disgenet.org/web/DisGeNET) are indicated in green circles. Interactions between red circles or between red and green circles are indicated by bold lines. Molecules represented by gray circles are putative mediators of interactions between the genes.

Characteristics of subjects with hypertriglyceridemia and control individuals.

Characteristic Control Hypertriglyceridemia P-value
Number of subjects 5,294 2,664
Age (years) 51.3±10.2 53.3±8.8 <0.0001
Sex (men/women, %) 50.2/49.8 75.6/24.4 <0.0001
Smoking (%) 35.9 54.0 <0.0001
Obesity (%) 22.9 42.6 <0.0001
Body mass index (kg/m2) 22.7±3.4 24.8±3.6 <0.0001
Hypertension (%) 35.3 57.2 <0.0001
Systolic BP (mmHg) 125±23 132±23 <0.0001
Diastolic BP (mmHg) 75±14 80±13 <0.0001
Diabetes mellitus (%) 17.5 33.8 <0.0001
Fasting plasma glucose (mmol/l) 5.83±2.04 6.55±2.81 <0.0001
Blood hemoglobin A1c (%) 5.83±1.08 6.26±1.50 <0.0001
Serum triglycerides (mmol/l) 0.94±0.34 2.40±1.37 <0.0001
Serum HDL-cholesterol (mmol/l) 1.66±0.47 1.30±0.36 <0.0001
Serum LDL-cholesterol (mmol/l) 3.06±0.80 3.35±0.95 0.8593
Chronic kidney disease (%) 12.3 19.9 <0.0001
Serum creatinine (µmol/l) 71.9±69.8 82.1±85.2 <0.0001
eGFR (ml min−1 1.73 m−2) 78.5±19.4 74.1±21.6 <0.0001
Hyperuricemia (%) 11.7 28.4 <0.0001
Serum uric acid (µmol/l) 308±90 362±91 <0.0001

Quantitative data are presented as mean ± standard deviation and were compared between subjects with hypertriglyceridemia and controls with the unpaired Student’s t-test. Categorical data were compared between the two groups with Pearson’s Chi-square test. Based on Bonferroni’s correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

Characteristics of subjects with hypo-HDL-cholesterolemia and control individuals.

Characteristic Control Hypo-HDL-cholesterolemia P-value
Number of subjects 7,085 974
Age (years) 51.7±9.9 54.3±8.7 <0.0001
Sex (men/women, %) 55.1/44.9 85.3/14.7 <0.0001
Smoking (%) 40.5 54.6 <0.0001
Obesity (%) 27.0 48.2 <0.0001
Body mass index (kg/m2) 23.2±3.5 25.1±3.9 <0.0001
Hypertension (%) 39.6 64.8 <0.0001
Systolic BP (mmHg) 126±23 137±27 <0.0001
Diastolic BP (mmHg) 76±14 80±16 <0.0001
Diabetes mellitus (%) 19.5 48.2 <0.0001
Fasting plasma glucose (mmol/l) 5.93±2.16 7.16±3.26 <0.0001
Blood hemoglobin A1c (%) 5.89±1.17 6.59±1.60 <0.0001
Serum triglycerides (mmol/l) 1.35±0.96 2.12±1.62 <0.0001
Serum HDL-cholesterol (mmol/l) 1.63±0.42 0.88±0.12 <0.0001
Serum LDL-cholesterol (mmol/l) 3.16±0.84 3.13±0.99 0.2860
Chronic kidney disease (%) 13.4 26.2 <0.0001
Serum creatinine (µmol/l) 72.6±66.6 96.0±122.7 <0.0001
eGFR (ml min−1 1.73 m−2) 77.5±18.5 73.3±29.8 <0.0001
Hyperuricemia (%) 15.9 27.2 <0.0001
Serum uric acid (µmol/l) 323±91 361±0.3 <0.0001

Quantitative data are presented as mean ± standard deviation and were compared between subjects with hypo-HDL-cholesterolemia and controls with the unpaired Student’s t-test. Categorical data were compared between the two groups with Pearson’s Chi-square test. Based on Bonferroni’s correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

Characteristics of subjects with hyper-LDL-cholesterolemia and control individuals.

Characteristic Control Hyper-LDL-cholesterolemia P-value
Number of subjects 5,111 2,911
Age (years) 51.3±10.3 53.2±8.9 <0.0001
Sex (men/women, %) 59.0/41.0 58.2/41.8 0.4936
Smoking (%) 40.9 44.3 0.0034
Obesity (%) 27.7 32.6 <0.0001
Body mass index (kg/m2) 23.2±3.6 23.9±3.5 <0.0001
Hypertension (%) 42.5 42.6 0.8966
Systolic BP (mmHg) 128±25 126±21 0.0025
Diastolic BP (mmHg) 76±14 77±13 0.0004
Diabetes mellitus (%) 23.2 22.0 0.2593
Fasting plasma glucose (mmol/l) 6.11±2.49 6.02±2.12 0.0831
Blood hemoglobin A1c (%) 5.96±1.25 5.99±1.26 0.4573
Serum triglycerides (mmol/l) 1.40±1.19 1.52±0.91 <0.0001
Serum HDL-cholesterol (mmol/l) 1.56±0.49 1.51±0.42 <0.0001
Serum LDL-cholesterol (mmol/l) 2.70±0.56 3.90±0.74 <0.0001
Chronic kidney disease (%) 15.3 14.3 0.2118
Serum creatinine (µmol/l) 78.3±88.7 71.7±58.9 0.0001
eGFR (ml min−1 1.73 m−2) 77.0±21.7 76.8±17.8 0.7007
Hyperuricemia (%) 16.3 18.9 0.0028
Serum uric acid (µmol/l) 323±97 334±87 <0.0001

Quantitative data are presented as mean ± standard deviation and were compared between subjects with hyper-LDL-cholesterolemia and controls with the unpaired Student’s t-test. Categorical data were compared between the two groups with Pearson’s Chi-square test. Based on Bonferroni’s correction, P<0.0026 (0.05/19) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

The 25 SNPs significantly associated with hypertriglyceridemia in the exome-wide association study.

Gene SNP Nucleotide substitutiona Amino acid substitution Chromosome Position MAF (%) Allele OR Allele frequency (P-value)
APOA5 rs2075291 G/T G185C 11 116790676 7.3 1.89 2.83×10−24
BUD13 rs10790162 G/A 11 116639104 26.3 1.47 3.58×10−24
ZPR1 rs964184 C/G 11 116778201 26.3 1.46 8.82×10−24
APOA5 rs2266788 T/C 11 116789970 26.2 1.47 1.27×10−23
rs7350481 C/T 11 116715567 27.7 1.44 7.94×10−23
rs9326246 G/C 11 116741017 26.5 1.45 1.36×10−22
ZPR1 rs2075290 T/C 11 116782580 26.7 1.43 1.58×10−21
rs12678919 A/G 8 19986711 12.6 0.71 6.07×10−11
rs10503669 C/A 8 19990179 12.6 0.71 8.32×10−11
rs17482753 G/T 8 19975135 12.6 0.72 2.04×10−10
rs10096633 C/T 8 19973410 12.7 0.72 2.50×10−10
LPL rs328 C/G S474* 8 19962213 12.9 0.72 2.72×10−10
APOA4 rs5104 A/G N147S 11 116821618 35.7 1.25 2.78×10−10
rs7016880 G/C 8 20019235 12.0 0.72 1.72×10−9
GCKR rs1260326 T/C L446P 2 27508073 43.6 0.82 6.27×10−9
GCKR rs780093 A/G 2 27519736 43.0 0.83 2.18×10−8
rs1260333 T/C 2 27525757 42.9 0.83 4.38×10−8
rs11085421 A/C 19 20985948 19.1 0.79 1.59×10−7
rs1441756 T/G 8 20010875 19.0 0.80 5.61×10−7
rs2083637 T/C 8 20007664 19.0 0.81 6.24×10−7
LPL rs301 T/C 8 19959423 19.3 0.81 7.70×10−7
LPL rs13702 A/G 8 19966981 19.2 0.81 9.15×10−7
LPL rs15285 G/A 8 19967156 19.2 0.81 1.02×10−6
rs2954033 G/A 8 125481504 33.3 1.19 1.02×10−6
LPL rs326 A/G 8 19961928 19.4 0.81 1.24×10−6

Allele frequencies were analyzed with Fisher’s exact test. P<1.60×10−6 was considered statistically significant.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

The 28 SNPs significantly associated with hypo-HDL-cholesterolemia in the exome-wide association study.

Gene SNP Nucleotide substitutiona Amino acid substitution Chromosome Position MAF (%) Allele OR Allele frequency (P-value)
LPGAT1 rs150552771 T/C K200E 1 211783358 5.0 16.67 1.09×10−12
APOA5 rs2075291 G/T G185C 11 116790676 7.3 1.79 4.10×10−12
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 0.18 4.51×10−11
ZNF860 rs140232911 C/T S161L 3 31989561 10.4 4.39 5.21×10−11
rs9261800 C/G 6 30408822 2.8 19.65 6.69×10−11
VPS33B rs199921354 C/T R80Q 15 91013841 1.2 0.17 1.03×10−10
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 0.19 1.33×10−10
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 0.18 1.46×10−10
COL6A3 rs146092501 C/T E1386K 2 237371861 1.2 0.18 2.10×10−10
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 0.19 2.74×10−10
PLCB2 rs200787930 C/T E1106K 15 40289298 1.2 0.19 2.79×10−10
MOB3C rs139537100 C/T R24Q 1 46615006 1.2 0.19 2.87×10−10
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 0.19 3.94×10−10
EHD3 rs116417209 G/A V151I 2 31249417 3.5 12.5 5.66×10−10
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 0.20 1.17×10−9
OR4F6 rs141569282 G/A A117T 15 101806068 1.7 0.23 2.31×10−9
ACAD10 rs11066015 G/A 12 111730205 27.5 1.37 2.61×10−9
CACNA1D rs35874056 G/A G460S 3 53702798 2.0 100.00 2.95×10−9
ALDH2 rs671 G/A E504K 12 111803962 27.6 1.35 4.23×10−9
rs3764261 G/T 16 56959412 19.8 0.69 7.90×10−9
rs247616 C/T 16 56955678 19.7 0.69 9.31×10−9
BRAP rs3782886 A/G 12 111672685 29.3 1.34 1.19×10−8
CETP rs1532624 G/T 16 56971567 29.6 0.74 2.63×10−8
HECTD4 rs11066280 T/A 12 112379979 29.0 1.33 3.54×10−8
HECTD4 rs2074356 C/T 12 112207597 25.4 1.32 1.43×10−7
LILRB2 rs73055442 C/T R103H 19 54279838 1.6 34.09 1.80×10−7
DCLRE1C rs150854849 C/T R179Q 10 14934704 2.4 59.56 3.16×10−7
SPOPL rs114501427 G/A D349N 2 138568946 8.8 3.23 4.01×10−7

Allele frequencies were analyzed with Fisher’s exact test. P<1.61×10−6 was considered statistically significant.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

The 65 SNPs significantly associated with hyper-LDL-cholesterolemia in the exome-wide association study.

Gene SNP Nucleotide substitutiona Amino acid substitution Chromosome Position MAF (%) Allele OR Allele frequency (P-value)
APOE rs7412 C/T R176C 19 44908822 4.3 0.42 6.62×10−22
COL6A3 rs146092501 C/T E1386K 2 237371861 1.2 2.14 1.42×10−11
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 2.13 1.83×10−11
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 2.10 1.95×10−11
VPS33B rs199921354 C/T R80Q 15 91013841 1.2 2.11 2.32×10−11
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 2.08 4.91×10−11
MOB3C rs139537100 C/T R24Q 1 46615006 1.2 2.06 5.58×10−11
PLCB2 rs200787930 C/T E1106K 15 40289298 1.2 2.03 1.70×10−10
MUC17 rs78010183 A/T T1305S 7 101035329 1.8 1.81 2.30×10−10
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 2.01 3.49×10−10
APOB rs13306206 G/A P955S 2 21019859 3.2 1.75 7.32×10−10
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 1.92 9.85×10−10
PTCH2 rs147284320 C/T V503I 1 44828589 2.0 1.86 1.23×10−9
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 1.94 1.49×10−9
APOC1 rs445925 C/T 19 44912383 6.6 0.66 3.62×10−9
HSPA1B rs6457452 C/T 6 31827773 9.7 1.33 2.97×10−8
C6orf48 rs11968400 C/T 6 31836952 9.7 1.33 3.96×10−8
rs12210887 G/T 6 31847946 9.7 1.33 5.26×10−8
UBD rs64036 C/A 6 29559490 22.5 1.23 7.55×10−8
CCHCR1 rs147733073 C/G H539Q 6 31145462 10.2 1.32 8.01×10−8
VARS rs11751198 G/A 6 31785749 9.5 1.33 8.12×10−8
rs2596574 G/A 6 31366397 9.7 1.32 8.83×10−8
LY6G6F rs9267547 G/A A107T 6 31707724 10.0 1.32 9.72×10−8
NEU1 rs13118 T/A 6 31859509 9.7 1.32 1.01×10−7
SLC17A3 rs34902660 C/A G239V 6 25850874 8.4 1.35 1.04×10−7
FAM65B rs150142878 C/T R371Q 6 24847657 5.6 1.42 1.18×10−7
TUBB rs9500864 G/A 6 30725455 20.4 1.23 1.19×10−7
rs204999 A/G 6 32142202 9.1 1.33 1.34×10−7
rs3130663 A/G 6 30698817 10.7 1.28 1.38×10−7
VARS rs5030798 G/A V1055I 6 31779733 9.5 1.32 1.43×10−7
LY6G6F rs9267546 G/A 6 31705659 9.8 1.32 1.44×10−7
PRRC2A rs11538264 G/A V1774M 6 31635412 9.5 1.32 1.55×10−7
DPCR1 rs11970154 G/C G1213R 6 30952101 13.3 1.28 1.60×10−7
MSH5 rs11754464 C/T 6 31755958 9.5 1.32 1.73×10−7
PCSK9 rs151193009 C/T R93C 1 55043912 1.1 0.42 1.85×10−7
GABBR1 rs29243 C/T 6 29631325 10.6 1.30 1.94×10−7
KIAA0319 rs4576240 G/T P133T 6 24596250 5.5 1.41 2.10×10−7
LY6G6F rs17200983 C/A P34Q 6 31707506 9.5 1.32 2.38×10−7
TNXB rs140770834 C/G L2271V 6 32064851 8.8 1.32 2.42×10−7
TNXB rs11751545 A/C 6 32073266 8.8 1.32 2.42×10−7
DPCR1 rs6933400 C/T 6 30939399 13.2 1.27 2.43×10−7
LY6G6C rs117894946 G/C G75A 6 31719250 9.5 1.32 2.66×10−7
SLC44A4 rs117127493 G/C E344Q 6 31869232 8.9 1.32 3.22×10−7
ZSCAN26 rs76463649 A/G N15S 6 28271963 9.6 1.30 4.26×10−7
DHX16 rs7749235 T/C 6 30667816 17.8 1.23 4.67×10−7
LOC105-375015 rs9264942 T/C 6 31306603 40.1 1.18 4.82×10−7
ZSCAN31 rs6922302 C/G P128A 6 28327533 9.6 1.30 5.06×10−7
MDC1 rs2269702 A/G 6 30707358 17.7 1.23 5.13×10−7
MDC1 rs28986465 C/T P386L 6 30712785 17.7 1.23 5.17×10−7
MDC1 rs2075015 G/A E371K 6 30712831 17.7 1.23 5.17×10−7
DHX16 rs2285321 T/C 6 30670221 17.8 1.23 5.18×10−7
SKIV2L rs492899 A/G 6 31965741 9.1 1.31 5.33×10−7
MDC1 rs6924270 A/G 6 30714203 17.8 1.23 5.81×10−7
rs2508015 C/T 6 31042423 11.7 1.27 6.07×10−7
TUBB rs25527 C/T 6 30723161 21.0 1.22 6.08×10−7
PPP1R18 rs9468805 G/A 6 30675932 17.7 1.23 7.07×10−7
DHX16 rs6937357 T/C 6 30672547 17.8 1.23 7.07×10−7
HECTD4 rs11066280 T/A 12 112379979 29.0 1.19 7.09×10−7
TRIM40 rs2523995 G/A 6 30134407 10.6 1.28 7.88×10−7
PPP1R18 rs6457254 C/T 6 30681357 17.9 1.22 1.20×10−6
TUBB rs3132584 C/A 6 30720650 21.2 1.20 1.22×10−6
rs3130685 T/C 6 31238429 41.6 0.85 1.43×10−6
GIT2 rs2292354 C/T 12 109930396 26.2 0.83 1.45×10−6
PPP1R18 rs2394392 T/G 6 30682541 18.0 1.22 1.50×10−6
rs2524272 T/C 6 29714623 26.8 1.19 1.55×10−6

Allele frequencies were analyzed with Fisher’s exact test. P<1.60×10−6 was considered statistically significant.

Major allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele frequency; OR, odds ratio.

Association of SNPs to hypertriglyceridemia as determined by multivariable logistic regression analysis.

Gene SNP Dominant
Recessive
Additive 1
Additive 2
P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
APOA5 rs2075291 G/T <0.0001 1.99 1.74-2.28 <0.0001 3.19 1.79-5.66 <0.0001 1.93 1.68-2.22 <0.0001 3.50 1.97-6.22
BUD13 rs10790162 G/A <0.0001 1.66 1.51-1.83 <0.0001 1.80 1.50-2.15 <0.0001 1.58 1.42-1.75 <0.0001 2.17 1.81-2.62
ZPR1 rs964184 C/G <0.0001 1.67 1.51-1.84 <0.0001 1.74 1.46-2.09 <0.0001 1.59 1.44-1.76 <0.0001 2.12 1.76-2.56
APOA5 rs2266788 T/C <0.0001 1.67 1.51-1.84 <0.0001 1.74 1.45-2.09 <0.0001 1.59 1.44-1.76 <0.0001 2.11 1.75-2.55
rs7350481 C/T <0.0001 1.65 1.50-1.82 <0.0001 1.68 1.41-2.00 <0.0001 1.58 1.42-1.75 <0.0001 2.06 1.72-2.47
rs9326246 G/C <0.0001 1.64 1.49-1.81 <0.0001 1.75 1.46-2.09 <0.0001 1.56 1.41-1.73 <0.0001 2.11 1.75-2054
ZPR1 rs2075290 T/C <0.0001 1.62 1.47-1.78 <0.0001 1.70 1.42-2.04 <0.0001 1.54 1.39-1.71 <0.0001 2.05 1.70-2.46
rs12678919 A/G <0.0001 0.70 0.62-0.79 0.0362 0.62 0.39-0.97 <0.0001 0.71 0.63-0.80 0.0163 0.57 0.36-0.90
rs10503669 C/A <0.0001 0.70 0.62-0.79 0.0434 0.63 0.40-0.99 <0.0001 0.71 0.63-0.80 0.0199 0.58 0.37-0.92
rs17482753 G/T <0.0001 0.71 0.63-0.80 0.0357 0.62 0.40-0.97 <0.0001 0.72 0.64-0.82 0.0163 0.58 0.37-0.90
rs10096633 C/T <0.0001 0.71 0.64-0.80 0.0306 0.61 0.39-0.96 <0.0001 0.72 0.64-0.82 0.0138 0.57 0.37-0.89
LPL rs328 C/G <0.0001 0.72 0.64-0.81 0.0253 0.61 0.39-0.94 <0.0001 0.73 0.64-0.82 0.0110 0.57 0.37-0.88
APOA4 rs5104 A/G <0.0001 1.38 1.25-1.52 <0.0001 1.37 1.19-1.58 <0.0001 1.32 1.19-1.47 <0.0001 1.60 1.37-1.86
rs7016880 G/C <0.0001 0.72 0.64-0.82 0.0548 <0.0001 0.73 0.65-0.83 0.0327 0.61 0.39-0.96
GCKR rs1260326 T/C <0.0001 0.75 0.68-0.83 <0.0001 0.77 0.68-0.88 <0.0001 0.78 0.70-0.87 <0.0001 0.67 0.58-0.77
GCKR rs780093 A/G <0.0001 0.77 0.69-0.85 <0.0001 0.77 0.68-0.88 <0.0001 0.80 0.72-0.89 <0.0001 0.68 0.59-0.78
rs1260333 T/C <0.0001 0.77 0.70-0.86 <0.0001 0.77 0.68-0.88 0.0001 0.81 0.73-0.90 <0.0001 0.68 0.59-0.78
rs11085421 A/C <0.0001 0.78 0.70-0.86 0.0032 0.66 0.49-0.87 <0.0001 0.80 0.72-0.89 0.0007 0.61 0.46-0.81
rs1441756 T/G <0.0001 0.79 0.71-0.88 0.0125 0.70 0.53-0.93 <0.0001 0.81 0.72-0.90 0.0032 0.66 0.49-0.87
rs2083637 T/C <0.0001 0.79 0.71-0.88 0.0166 0.71 0.54-0.94 <0.0001 0.81 0.72-0.90 0.0044 0.66 0.50-0.88
LPL rs301 T/C <0.0001 0.79 0.72-0.88 0.0107 0.70 0.53-0.92 0.0001 0.81 0.73-0.90 0.0027 0.66 0.50-0.86
LPL rs13702 A/G <0.0001 0.80 0.72-0.88 0.0130 0.71 0.54-0.93 0.0001 0.81 0.73-0.90 0.0034 0.66 0.50-0.87
LPL rs15285 G/A <0.0001 0.80 0.72-0.88 0.0149 0.71 0.54-0.94 0.0001 0.81 0.73-0.91 0.0040 0.67 0.51-0.88
rs2954033 G/A <0.0001 1.26 1.14-1.39 0.0011 1.28 1.10-1.49 0.0001 1.22 1.10-1.35 <0.0001 1.42 1.21-1.67
LPL rs326 A/G <0.0001 0.80 0.72-0.88 0.0233 0.73 0.56-0.96 0.0001 0.81 0.73-0.90 0.0062 0.69 0.52-0.90

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, P<0.0005 (0.05/100) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Association of SNPs to hypo-HDL-cholesterolemia as determined by multivariable logistic regression analysis.

Gene SNP Dominant
Recessive
Additive 1
Additive 2
P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
LPGAT1 rs150552771 T/C <0.0001 19.16 8.16-45.01 <0.0001 19.16 8.16-45.01
APOA5 rs2075291 G/T <0.0001 1.85 1.55-2.20 0.0031 2.66 1.39-5.07 <0.0001 1.80 1.50-2.16 0.0012 2.91 1.52-5.57
COL6A5 rs200982668 G/A <0.0001 0.18 0.09-0.35 <0.0001 0.18 0.09-0.35
ZNF860 rs140232911 C/T <0.0001 4.88 3.12-7.63 <0.0001 4.88 3.12-7.63
rs9261800 C/G <0.0001 28.11 10.15-77.87 <0.0001 28.11 10.15-77.87
VPS33B rs199921354 C/T <0.0001 0.17 0.08-0.34 <0.0001 0.17 0.08-0.34
ADGRL3 rs192210727 G/T <0.0001 0.19 0.10-0.37 0.2341 <0.0001 0.19 0.10-0.38 0.9964
TMOD4 rs115287176 G/A <0.0001 0.17 0.08-0.35 <0.0001 0.17 0.08-0.35
COL6A3 rs146092501 C/T <0.0001 0.17 0.08-0.35 <0.0001 0.17 0.08-0.35
MARCH1 rs61734696 G/T <0.0001 0.19 0.10-0.37 <0.0001 0.19 0.10-0.37
PLCB2 rs200787930 C/T <0.0001 0.19 0.10-0.36 <0.0001 0.19 0.10-0.36
MOB3C rs139537100 C/T <0.0001 0.19 0.10-0.37 <0.0001 0.19 0.10-0.37
CXCL8 rs188378669 G/T <0.0001 0.19 0.10-0.36 <0.0001 0.19 0.10-0.36
EHD3 rs116417209 G/A <0.0001 14.34 6.16-33.35 <0.0001 14.34 6.16-33.35
ZNF77 rs146879198 G/A <0.0001 0.19 0.10-0.38 <0.0001 0.19 0.10-0.38
OR4F6 rs141569282 G/A <0.0001 0.25 0.13-0.46 <0.0001 0.25 0.13-0.46
ACAD10 rs11066015 G/A <0.0001 1.40 1.22-1.60 <0.0001 1.56 1.26-1.93 0.0003 1.32 1.14-1.52 <0.0001 1.77 1.42-2.22
CACNA1D rs35874056 G/A <0.0001 92.59 11.37-753.91 <0.0001 92.59 11.37-753.91
ALDH2 rs671 G/A <0.0001 1.39 1.21-1.60 <0.0001 1.55 1.25-1.92 0.0003 1.31 1.13-1.52 <0.0001 1.76 1.40-2.20
rs3764261 G/T <0.0001 0.68 0.58-0.79 0.0004 0.39 0.23-0.66 <0.0001 0.72 0.61-0.84 0.0001 0.35 0.21-0.60
rs247616 C/T <0.0001 0.68 0.58-0.79 0.0009 0.43 0.26-0.71 <0.0001 0.71 0.61-0.83 0.0002 0.39 0.24-0.64
BRAP rs3782886 A/G <0.0001 1.39 1.21-1.60 <0.0001 1.52 1.24-1.87 0.0003 1.31 1.13-1.52 <0.0001 1.74 1.40-2.17
CETP rs1532624 G/T <0.0001 0.73 0.64-0.84 <0.0001 0.50 0.37-0.67 0.0021 0.80 0.69-0.92 <0.0001 0.45 0.33-0.61
HECTD4 rs11066280 T/A <0.0001 1.42 1.23-1.63 0.0010 1.43 1.15-1.76 <0.0001 1.36 1.17-1.58 <0.0001 1.66 1.32-2.08
HECTD4 rs2074356 C/T <0.0001 1.37 1.19-1.57 0.0016 1.45 1.15-1.83 0.0002 1.32 1.14-1.52 <0.0001 1.64 1.29-2.09
LILRB2 rs73055442 C/T <0.0001 51.91 10.66-252.93 <0.0001 51.91 10.66-252.93
DCLRE1C rs150854849 C/T <0.0001 78.09 9.17-665.03 <0.0001 78.09 9.17-665.03
SPOPL rs114501427 G/A <0.0001 3.54 2.24-5.61 <0.0001 3.54 2.24-5.61

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, P<0.0004 (0.05/112) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Association of SNPs to hyper-LDL-cholesterolemia as determined by multivariable logistic regression analysis.

Gene SNP Dominant
Recessive
Additive 1
Additive 2
P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value OR 95% CI
APOE rs7412 C/T <0.0001 0.40 0.33-0.48 0.0738 <0.0001 0.40 0.33-0.49 0.0984
COL6A3 rs146092501 C/T <0.0001 2.34 1.87-2.93 <0.0001 2.34 1.87-2.93
TMOD4 rs115287176 G/A <0.0001 2.33 1.86-2.91 <0.0001 2.33 1.86-2.91
CXCL8 rs188378669 G/T <0.0001 2.30 1.85-2.87 <0.0001 2.30 1.85-2.87
VPS33B rs199921354 C/T <0.0001 2.31 1.85-2.89 <0.0001 2.31 1.85-2.89
ZNF77 rs146879198 G/A <0.0001 2.30 1.84-2.87 <0.0001 2.30 1.84-2.87
MOB3C rs139537100 C/T <0.0001 2.27 1.82-2.83 <0.0001 2.27 1.82-2.83
PLCB2 rs200787930 C/T <0.0001 2.22 1.78-2.77 <0.0001 2.22 1.78-2.77
MUC17 rs78010183 A/T <0.0001 1.99 1.65-2.40 <0.0001 1.99 1.65-2.40
MARCH1 rs61734696 G/T <0.0001 2.20 1.77-2.74 <0.0001 2.20 1.77-2.74
APOB rs13306206 G/A <0.0001 1.69 1.41-2.03 0.0145 5.13 1.38-19.03 <0.0001 1.65 1.37-1.98 0.0127 5.30 1.43-19.67
COL6A5 rs200982668 G/A <0.0001 2.12 1.71-2.63 <0.0001 2.12 1.71-2.63
PTCH2 rs147284320 C/T <0.0001 2.02 1.65-2.49 <0.0001 2.02 1.65-2.49
ADGRL3 rs192210727 G/T <0.0001 2.14 1.72-2.66 0.8431 <0.0001 2.17 1.74-2.71 0.8732
APOC1 rs445925 C/T <0.0001 0.63 0.55-0.73 0.8258 <0.0001 0.63 0.54-0.73 0.7212
HSPA1B rs6457452 C/T <0.0001 1.37 1.22-1.53 0.0284 1.51 1.04-2.20 <0.0001 1.35 1.20-1.52 0.0125 1.61 1.11-2.33
C6orf48 rs11968400 C/T <0.0001 1.37 1.22-1.53 0.0425 1.48 1.01-2.15 <0.0001 1.36 1.21-1.52 0.0195 1.57 1.07-2.29
rs12210887 G/T <0.0001 1.37 1.22-1.53 0.0590 <0.0001 1.36 1.21-1.52 0.0272 1.53 1.05-2.24
UBD rs64036 C/A <0.0001 1.28 1.17-1.40 0.0043 1.30 1.09-1.56 <0.0001 1.26 1.14-1.38 0.0002 1.42 1.18-1.71
CCHCR1 rs147733073 C/G <0.0001 1.37 1.22-1.53 0.1210 <0.0001 1.36 1.21-1.53 0.0592
VARS rs11751198 G/A <0.0001 1.36 1.22-1.52 0.0505 <0.0001 1.35 1.20-1.51 0.0238 1.56 1.06-2.29
rs2596574 G/A <0.0001 1.36 1.22-1.53 0.0807 <0.0001 1.35 1.21-1.52 0.0377 1.48 1.02-2.14
LY6G6F rs9267547 G/A <0.0001 1.35 1.21-1.51 0.0797 <0.0001 1.34 1.20-1.51 0.0370 1.47 1.02-2.11
NEU1 rs13118 T/A <0.0001 1.36 1.21-1.52 0.0450 1.47 1.01-2.16 <0.0001 1.34 1.20-1.51 0.0217 1.56 1.07-2.29
SLC17A3 rs34902660 C/A <0.0001 1.40 1.24-1.57 0.2131 <0.0001 1.40 1.24-1.57 0.1319
FAM65B rs150142878 C/T <0.0001 1.48 1.29-1.70 0.5456 <0.0001 1.49 1.30-1.71 0.4556
TUBB rs9500864 G/A <0.0001 1.28 1.16-1.40 0.0025 1.36 1.11-1.66 <0.0001 1.25 1.13-1.38 0.0002 1.47 1.20-1.81
rs204999 A/G <0.0001 1.37 1.22-1.53 0.1767 <0.0001 1.37 1.22-1.54 0.1002
rs3130663 A/G <0.0001 1.35 1.21-1.49 0.1104 <0.0001 1.34 1.21-1.50 0.0388 1.39 1.02-1.90
VARS rs5030798 G/A <0.0001 1.35 1.21-1.52 0.0609 <0.0001 1.34 1.19-1.51 0.0296 1.53 1.04-2.24
LY6G6F rs9267546 G/A <0.0001 1.35 1.21-1.51 0.1053 <0.0001 1.35 1.20-1.51 0.0525
PRRC2A rs11538264 G/A <0.0001 1.36 1.21-1.52 0.0873 <0.0001 1.35 1.20-1.51 0.0437 1.48 1.01-2.16
DPCR1 rs11970154 G/C <0.0001 1.33 1.20-1.47 0.1235 <0.0001 1.33 1.19-1.47 0.0445 1.37 1.01-1.86
MSH5 rs11754464 C/T <0.0001 1.35 1.21-1.51 0.0735 <0.0001 1.34 1.19-1.51 0.0365 1.50 1.03-2.20
PCSK9 rs151193009 C/T <0.0001 0.41 0.29-0.59 0.4126 <0.0001 0.42 0.29-0.59 0.9943
GABBR1 rs29243 C/T <0.0001 1.34 1.20-1.50 0.0562 <0.0001 1.33 1.19-1.49 0.244 1.50 1.05-2.13
KIAA0319 rs4576240 G/T <0.0001 1.47 1.29-1.69 0.7773 <0.0001 1.49 1.29-1.71 0.6763
LY6G6F rs17200983 C/A <0.0001 1.35 1.20-1.51 0.0873 <0.0001 1.34 1.19-1.50 0.0444 1.48 1.01-2.16
TNXB rs140770834 C/G <0.0001 1.36 1.21-1.53 0.1723 <0.0001 1.36 1.21-1.53 0.1013
TNXB rs11751545 A/C <0.0001 1.36 1.21-1.53 0.1723 <0.0001 1.36 1.21-1.53 0.1013
DPCR1 rs6933400 C/T <0.0001 1.32 1.20-1.47 0.1222 <0.0001 1.32 1.19-1.47 0.0456 1.37 1.01-1.87
LY6G6C rs117894946 G/C <0.0001 1.35 1.20-1.51 0.0871 <0.0001 1.34 1.19-1.50 0.0445 1.48 1.01-2.16
SLC44A4 rs117127493 G/C <0.0001 1.36 1.21-1.52 0.2033 <0.0001 1.36 1.20-1.53 0.1218
ZSCAN26 rs76463649 A/G <0.0001 1.36 1.21-1.52 0.3394 <0.0001 1.36 1.21-1.53 0.2111
DHX16 rs7749235 T/C <0.0001 1.28 1.16-1.40 0.0064 1.37 1.09-1.72 <0.0001 1.25 1.13-1.38 0.0010 1.47 1.17-1.86
LOC105- rs9264942 T/C <0.0001 1.26 1.14-1.39 0.0004 1.24 1.10-1.39 0.0002 1.21 1.09-1.35 <0.0001 1.38 1.21-1.58
375015
ZSCAN31 rs6922302 C/G <0.0001 1.36 1.21-1.52 0.3391 <0.0001 1.36 1.21-1.53 0.2111
MDC1 rs2269702 A/G <0.0001 1.27 1.16-1.40 0.0048 1.39 1.11-1.75 <0.0001 1.25 1.13-1.38 0.0007 1.49 1.18-1.88
MDC1 rs28986465 C/T <0.0001 1.27 1.16-1.40 0.0048 1.39 1.11-1.75 <0.0001 1.24 1.13-1.38 0.0007 1.49 1.18-1.88
MDC1 rs2075015 G/A <0.0001 1.27 1.16-1.40 0.0048 1.39 1.11-1.75 <0.0001 1.24 1.13-1.38 0.0007 1.49 1.18-1.88
DHX16 rs2285321 T/C <0.0001 1.27 1.16-1.40 0.0056 1.38 1.10-1.73 <0.0001 1.25 1.13-1.38 0.0008 1.48 1.18-1.87
SKIV2L rs492899 A/G <0.0001 1.34 1.20-1.51 0.1465 <0.0001 1.34 1.19-1.51 0.0843
MDC1 rs6924270 A/G <0.0001 1.27 1.16-1.40 0.0055 1.38 1.10-1.74 <0.0001 1.25 1.13-1.38 0.0008 1.48 1.18-1.87
rs2508015 C/T <0.0001 1.30 1.17-1.45 0.0409 1.39 1.01-1.91 <0.0001 1.29 1.16-1.44 0.0166 1.47 1.07-2.02
TUBB rs25527 C/T <0.0001 1.26 1.14-1.38 0.0028 1.35 1.11-1.64 <0.0001 1.23 1.11-1.35 0.0002 1.45 1.19-1.78
PPP1R18 rs9468805 G/A <0.0001 1.27 1.15-1.39 0.0048 1.39 1.11-1.75 <0.0001 1.24 1.12-1.37 0.0007 1.49 1.18-1.87
DHX16 rs6937357 T/C <0.0001 1.27 1.15-1.39 0.0048 1.39 1.11-1.75 <0.0001 1.24 1.12-1.37 0.0007 1.49 1.18-1.87
HECTD4 rs11066280 T/A <0.0001 1.26 1.15-1.38 0.0083 1.23 1.05-1.43 <0.0001 1.24 1.13-1.37 0.0002 1.36 1.16-1.59
TRIM40 rs2523995 G/A <0.0001 1.34 1.20-1.49 0.2147 <0.0001 1.34 1.20-1.50 0.1152
PPP1R18 rs6457254 C/T <0.0001 1.26 1.15-1.39 0.0063 1.37 1.09-1.72 <0.0001 1.24 1.12-1.37 0.0010 1.47 1.17-1.85
TUBB rs3132584 C/A <0.0001 1.25 1.14-1.37 0.0035 1.34 1.10-1.63 <0.0001 1.22 1.11-1.35 0.0003 1.44 1.18-1.76
rs3130685 T/C 0.0005 0.80 0.71-0.91 <0.0001 0.82 0.74-0.90 0.0264 0.86 0.75-0.98 <0.0001 0.73 0.64-0.84
GIT2 rs2292354 C/T 0.0001 0.83 0.76-0.91 <0.0001 0.68 0.56-0.82 0.0050 0.87 0.79-0.96 <0.0001 0.64 0.52-0.78
PPP1R18 rs2394392 T/G <0.0001 1.26 1.15-1.39 0.0074 1.36 1.09-1.71 <0.0001 1.24 1.12-1.37 0.0012 1.46 1.16-1.84
rs2524272 T/C <0.0001 1.22 1.11-1.34 0.0010 1.30 1.11-1.52 0.0007 1.18 1.07-1.30 <0.0001 1.40 1.19-1.65

Multivariable logistic regression analysis was performed with adjustment for age and sex. Based on Bonferroni’s correction, P<0.0002 (0.05/260) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Association of SNPs identified in the present study to serum triglyceride concentration.

Gene SNP Serum triglycerides (mmol/l) P-value
APOA5 rs2075291 G/T GG GT TT <0.0001
1.39±0.98 1.83±1.55 2.56±2.27
BUD13 rs10790162 G/A GG GA AA <0.0001
1.35±1.00 1.54±1.18 1.77±1.31
ZPR1 rs964184 C/G CC CG GG <0.0001
1.35±1.00 1.55±1.18 1.75±1.30
APOA5 rs2266788 T/C TT TC CC <0.0001
1.35±1.00 1.54±1.17 1.76±1.30
rs7350481 C/T CC CT TT <0.0001
1.34±0.95 1.56±1.24 1.68±1.19
rs9326246 G/C GG GC CC <0.0001
1.35±1.00 1.54±1.18 1.74±1.28
ZPR1 rs2075290 T/C TT TC CC <0.0001
1.36±1.01 1.54±1.17 1.74±1.29
rs12678919 A/G AA AG GG <0.0001
1.49±1.11 1.33±1.03 1.32±1.37
rs10503669 C/A CC CA AA <0.0001
1.49±1.11 1.33±1.03 1.32±1.38
rs17482753 G/T GG GT TT <0.0001
1.49±1.11 1.33±1.02 1.31±1.35
rs10096633 C/T CC CT TT <0.0001
1.49±1.11 1.33±1.03 1.31±1.34
LPL rs328 C/G CC CG GG <0.0001
1.49±1.11 1.33±1.02 1.33±1.33
APOA4 rs5104 A/G AA AG GG <0.0001
1.37±1.00 1.49±1.12 1.57±1.28
rs7016880 G/C GG GC CC <0.0001
1.49±1.11 1.33±1.04 1.30±1.35
GCKR rs1260326 T/C TT TC CC <0.0001
1.54±1.14 1.44±1.14 1.33±0.89
GCKR rs780093 A/G AA AG GG <0.0001
1.53±1.12 1.45±1.16 1.33±0.87
rs1260333 T/C TT TC CC <0.0001
1.53±1.12 1.45±1.16 1.32±0.87
rs11085421 A/C AA AC CC <0.0001
1.49±1.14 1.39±1.05 1.27±0.70
rs1441756 T/G TT TG GG <0.0001
1.49±1.12 1.38±1.04 1.34±1.16
rs2083637 T/C TT TC CC <0.0001
1.49±1.12 1.38±1.05 1.34±1.16
LPL rs301 T/C TT TC CC <0.0001
1.49±1.11 1.38±1.08 1.34±1.14
LPL rs13702 A/G AA AG GG <0.0001
1.50±1.12 1.38±1.04 1.34±1.15
LPL rs15285 G/A GG GA AA <0.0001
1.50±1.12 1.38±1.04 1.34±1.15
rs2954033 G/A GG GA AA 0.0007
1.41±1.02 1.47±1.16 1.55±1.18
LPL rs326 A/G AA AG GG <0.0001
1.49±1.11 1.38±1.07 1.35±1.14

Data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni’s correction, P<0.0020 (0.05/25) was considered statistically significant. SNP, single nucleotide polymorphism.

Association of SNPs identified in the present study to serum HDL-cholesterol concentration.

Gene SNP Serum HDL-cholesterol (mmol/l) P-value
LPGAT1 rs150552771 T/C TT TC <0.0001
1.54±0.47 1.11±0.63
APOA5 rs2075291 G/T GG GT TT <0.0001
1.56±0.47 1.42±0.45 1.29±0.40
COL6A5 rs200982668 G/A GG GA <0.0001
1.53±0.47 1.69±0.44
ZNF860 rs140232911 C/T CC CT 0.0003
1.54±0.47 1.37±0.59
rs9261800 C/G CC CG <0.0001
1.54±0.47 0.98±0.56
VPS33B rs199921354 C/T CC CT <0.0001
1.53±0.47 1.69±0.44
ADGRL3 rs192210727 G/T GG GT TT <0.0001
1.53±0.47 1.67±0.44 1.91±0.49
TMOD4 rs115287176 G/A GG GA <0.0001
1.53±0.47 1.68±0.44
COL6A3 rs146092501 C/T CC CT <0.0001
1.53±0.47 1.68±0.44
MARCH1 rs61734696 G/T GG GT <0.0001
1.53±0.47 1.69±0.44
PLCB2 rs200787930 C/T CC CT <0.0001
1.53±0.47 1.69±0.44
MOB3C rs139537100 C/T CC CT <0.0001
1.53±0.47 1.68±0.44
CXCL8 rs188378669 G/T GG GT <0.0001
1.53±0.47 1.69±0.44
EHD3 rs116417209 G/A GG GA <0.0001
1.54±0.47 1.09±0.48
ZNF77 rs146879198 G/A GG GA <0.0001
1.53±0.47 1.69±0.44
OR4F6 rs141569282 G/A GG GA <0.0001
1.48±0.46 1.72±0.43
ACAD10 rs11066015 G/A GG GA AA <0.0001
1.57±0.48 1.51±0.47 1.43±0.43
CACNA1D rs35874056 G/A GG GA <0.0001
1.51±0.47 0.94±0.64
ALDH2 rs671 G/A GG GA AA <0.0001
1.57±0.48 1.51±0.47 1.43±0.43
rs3764261 G/T GG GT TT <0.0001
1.50±0.46 1.59±0.48 1.72±0.49
rs247616 C/T CC CT TT <0.0001
1.50±0.46 1.59±0.48 1.71±0.50
BRAP rs3782886 A/G AA AG GG <0.0001
1.57±0.48 1.52±0.47 1.44±0.43
CETP rs1532624 G/T GG GT TT <0.0001
1.50±0.46 1.56±0.47 1.64±0.48
HECTD4 rs11066280 T/A TT TA AA <0.0001
1.57±0.47 1.52±0.47 1.44±0.42
HECTD4 rs2074356 C/T CC CT TT <0.0001
1.57±0.48 1.51±0.47 1.44±0.43
LILRB2 rs73055442 C/T CC CT <0.0001
1.54±0.47 0.88±0.31
DCLRE1C rs150854849 C/T CC CT <0.0001
1.54±0.47 0.92±0.68
SPOPL rs114501427 G/A GG GA 0.0041
1.54±0.47 1.41±0.58

Data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni’s correction, P<0.0018 (0.05/28) was considered statistically significant. SNP, single nucleotide polymorphism; HDL, high density lipoprotein.

Association of SNPs identified in the present study to serum LDL-cholesterol concentration.

Gene SNP Serum LD L-cholesterol (mmol/l) P-value
APOE rs7412 C/T CC CT TT <0.0001
3.20±0.85 2.74±0.80 2.39±1.48
COL6A3 rs146092501 C/T CC CT 0.1168
3.16±0.86 3.24±0.82
TMOD4 rs115287176 G/A GG GA 0.1624
3.16±0.86 3.23±0.82
CXCL8 rs188378669 G/T GG GT 0.1158
3.16±0.86 3.24±0.82
VPS33B rs199921354 C/T CC CT 0.1121
3.16±0.86 3.24±0.81
ZNF77 rs146879198 G/A GG GA 0.2277
3.16±0.86 3.22±0.81
MOB3C rs139537100 C/T CC CT 0.2422
3.16±0.86 3.21±0.82
PLCB2 rs200787930 C/T CC CT 0.1860
3.16±0.86 3.22±0.81
MUC17 rs78010183 A/T AA AT 0.0096
3.15±0.87 3.26±0.78
MARCH1 rs61734696 G/T GG GT 0.3029
3.16±0.86 3.21±0.80
APOB rs13306206 G/A GG GA AA <0.0001
3.14±0.85 3.42±0.98 4.20±0.86
COL6A5 rs200982668 G/A GG GA 0.3549
3.16±0.86 3.20±0.80
PTCH2 rs147284320 C/T CC CT 0.5075
3.17±0.82 3.20±0.82
ADGRL3 rs192210727 G/T GG GT TT 0.6309
3.16±0.86 3.20±0.81 2.99±0.82
APOC1 rs445925 C/T CC CT TT <0.0001
3.19±0.86 2.96±0.86 2.99±1.21
HSPA1B rs6457452 C/T CC CT TT <0.0001
3.14±0.85 3.24±0.89 3.38±0.88
C6orf48 rs11968400 C/T CC CT TT <0.0001
3.14±0.85 3.24±0.89 3.37±0.88
rs12210887 G/T GG GT TT <0.0001
3.14±0.85 3.24±0.89 3.37±0.89
UBD rs64036 C/A CC CA AA 0.0004
3.13±0.85 3.19±0.87 3.27±0.85
CCHCR1 rs147733073 C/G CC CG GG <0.0001
3.14±0.85 3.23±0.89 3.37±0.88
VARS rs11751198 G/A GG GA AA <0.0001
3.14±0.85 3.24±0.89 3.37±0.89
rs2596574 G/A GG GA AA <0.0001
3.14±0.85 3.24±0.89 3.35±0.86
LY6G6F rs9267547 G/A GG GA AA <0.0001
3.14±0.85 3.23±0.89 3.37±0.89
NEU1 rs13118 T/A TT TA AA <0.0001
3.14±0.85 3.24±0.89 3.37±0.89
SLC17A3 rs34902660 C/A CC CA AA <0.0001
3.14±0.85 3.26±0.90 3.35±0.91
FAM65B rs150142878 C/T CC CT TT <0.0001
3.14±0.85 3.30±0.94 3.18±0.88
TUBB rs9500864 G/A GG GA AA 0.0002
3.13±0.85 3.19±0.87 3.28±0.90
rs204999 A/G AA AG GG <0.0001
3.14±0.85 3.24±0.89 3.36±0.91
rs3130663 A/G AA AG GG 0.0010
3.14±0.85 3.22±0.88 3.22±0.90
VARS rs5030798 G/A GG GA AA <0.0001
3.14±0.85 3.24±0.89 3.37±0.89
LY6G6F rs9267546 G/A GG GA AA <0.0001
3.14±0.85 3.24±0.89 3.36±0.87
PRRC2A rs11538264 G/A GG GA AA <0.0001
3.14±0.85 3.24±0.90 3.36±0.88
DPCR1 rs11970154 G/C GG GC CC <0.0001
3.13±0.85 3.23±0.89 3.32±0.86
MSH5 rs11754464 C/T CC CT TT <0.0001
3.14±0.85 3.24±0.89 3.37±0.89
PCSK9 rs151193009 C/T CC CT TT <0.0001
3.17±0.86 2.77±0.73 2.05
GABBR1 rs29243 C/T CC CT TT 0.0001
3.14±0.85 3.23±0.89 3.34±0.86
KIAA0319 rs4576240 G/T GG GT TT <0.0001
3.14±0.85 3.30±0.93 3.17±0.89
LY6G6F rs17200983 C/A CC CA AA <0.0001
3.14±0.85 3.24±0.89 3.36±0.88
TNXB rs140770834 C/G CC CG GG <0.0001
3.14±0.85 3.24±0.89 3.37±0.92
TNXB rs11751545 A/C AA AC CC <0.0001
3.14±0.85 3.24±0.89 3.37±0.92
DPCR1 rs6933400 C/T CC CT TT <0.0001
3.13±0.85 3.23±0.89 3.32±0.87
LY6G6C rs117894946 G/C GG GC CC <0.0001
3.14±0.85 3.24±0.89 3.36±0.88
SLC44A4 rs117127493 G/C GG GC CC <0.0001
3.14±0.85 3.24±0.89 3.36±0.91
ZSCAN26 rs76463649 A/G AA AG GG <0.0001
3.14±0.85 3.24±0.89 3.37±0.85
DHX16 rs7749235 T/C TT TC CC 0.0010
3.14±0.85 3.20±0.87 3.28±0.90
LOC105375015 rs9264942 T/C TT TC CC 0.0001
3.13±0.84 3.15±0.87 3.25±0.88
ZSCAN31 rs6922302 C/G CC CG GG <0.0001
3.14±0.85 3.24±0.90 3.37±0.85
MDC1 rs2269702 A/G AA AG GG 0.0013
3.14±0.85 3.20±0.87 3.28±0.91
MDC1 rs28986465 C/T CC CT TT 0.0013
3.14±0.85 3.20±0.87 3.28±0.91
MDC1 rs2075015 G/A GG GA AA 0.0013
3.14±0.85 3.20±0.87 3.28±0.91
DHX16 rs2285321 T/C TT TC CC 0.0011
3.14±0.85 3.20±0.87 3.28±0.91
SKIV2L rs492899 A/G AA AG GG 0.0001
3.14±0.85 3.23±0.89 3.36±0.91
MDC1 rs6924270 A/G AA AG GG 0.0012
3.14±0.85 3.20±0.87 3.28±0.91
rs2508015 C/T CC CT TT 0.0005
3.14±0.85 3.22±0.88 3.31±0.86
TUBB rs25527 C/T CC CT TT 0.0008
3.14±0.86 3.19±0.86 3.27±0.89
PPP1R18 rs9468805 G/A GG GA AA 0.0016
3.14±0.85 3.20±0.87 3.28±0.91
DHX16 rs6937357 T/C TT TC CC 0.0016
3.14±0.85 3.20±0.87 3.28±0.91
HECTD4 rs11066280 T/A TT TA AA 0.0005
3.12±0.88 3.19±0.85 3.24±0.81
TRIM40 rs2523995 G/A GG GA AA 0.0008
3.14±0.85 3.22±0.89 3.32±0.87
PPP1R18 rs6457254 C/T CC CT TT 0.0010
3.14±0.85 3.20±0.87 3.28±0.91
TUBB rs3132584 C/A CC CA AA 0.0008
3.13±0.86 3.19±0.86 3.27±0.90
rs3130685 T/C TT TC CC 0.0234
3.20±0.89 3.14±0.84 3.14±0.85
GIT2 rs2292354 C/T CC CT TT 0.0077
3.18±0.86 3.15±0.87 3.05±0.82
PPP1R18 rs2394392 T/G TT TG GG 0.0013
3.14±0.85 3.20±0.87 3.28±0.91
rs2524272 T/C TT TC CC 0.0005
3.13±0.86 3.18±0.87 3.27±0.87

Data are presented as mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based on Bonferroni’s correction, P<0.0008 (0.05/65) was considered statistically significant (indicated in bold). SNP, single nucleotide polymorphism; LDL, low density lipoprotein.

Relation of genes, chromosomal loci, and SNPs associated with hypertriglyceridemia in the present study to previously examined dyslipidemia-related phenotypes.

Gene/chr locus SNP Chr Position Previously examined phenotypes
GCKR rs1260326 2 27508073 Triglycerides (20686565, 21423719, 23063622, 22629316, 19060906, 18193043)
rs780093 2 27519736
2p23 rs1260333 2 27525757 Triglycerides (20686565, 19060906, 20864672, 19802338)
LPL rs301 8 19959423 Triglycerides (20686565)
rs326 19961928
rs328 19962213
rs13702 19966981
rs15285 19967156
8p21.3 rs10096633 8 19973410 Triglycerides (20686565, 19060906, 19060911, 21943158, 20139978, 23063622, 23505323, 19060910, 19802338)
8p21.3 rs17482753 8 19975135 Triglycerides (20686565, 23063622, 19060906, 18193043, 21943158, 18179892, 19913121, 17463246)
8p21.3 rs12678919 8 19986711 Triglycerides (20686565, 19060906, 21909109, 21943158, 20139978, 23063622, 23505323)
8p21.3 rs10503669 8 19990179 Triglycerides (20686565, 23063622, 21909109, 19060906, 18193043, 21943158, 19913121)
8p21.3 rs2083637 8 20007664 Triglycerides (20686565, 19060906, 19060911, 21943158, 19802338, 23063622)
8p21.3 rs1441756 8 20010875 Triglycerides (20686565, 19060906)
8p21.3 rs7016880 8 20019235 Triglycerides (20686565, 19060906)
8q24.2 rs2954033 8 125481504 Triglycerides (22479202, 20686565, 23063622, 19060906, 21386085)
BUD13 rs10790162 11 116639104 Triglycerides (20686565, 23202125, 23063622, 20139978, 19060906, 20864672, 18193046)
11q23.3 rs7350481 11 116715567 Triglycerides (20686565, 20139978, 19060906)
11q23.3 rs9326246 11 116741017 Triglycerides (23202125, 20686565, 19060906)
ZPR1 rs964184 11 116778201 Triglycerides (20686565, 23063622, 21909109, 19060906, 20864672, 22629316, 20139978, 21943158, 23505323, 23726366, 19913121)
rs2075290 11 116782580
APOA5 rs2266788 11 116789970 Triglycerides (20686565, 23063622, 22629316, 19060906, 21943158, 19913121, 18193043, 19802338, 23505323, 23236364)
rs2075291 11 116790676
APOA4 rs5104 11 116821618 Triglycerides (20686565, 23063622, 19060906, 23505323, 19197348, 19913121)
19p12 rs11085421 19 20985948 None

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database (https://grasp.nhlbi.nih.gov/Search.aspx) with a P-value of <1.0×10-6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr, chromosome.

Relation of genes, chromosomal loci and SNPs associated with hypo-HDL-cholesterolemia in the present study to previously examined dyslipidemia-related phenotypes.

Gene/chr locus SNP Chr Position Previously examined phenotypes
MOB3C rs139537100 1 46615006 None
TMOD4 rs115287176 1 151170961 None
LPGAT1 rs150552771 1 211783358 None
EHD3 rs116417209 2 31249417 None
SPOPL rs114501427 2 138568946 None
COL6A3 rs146092501 2 237371861 None
ZNF860 rs140232911 3 31989561 None
CACNA1D rs35874056 3 53702798 None
COL6A5 rs200982668 3 130470894 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
6p22.1 rs9261800 6 30408822 Type 1 diabetes (17554300)
DCLRE1C rs150854849 10 14934704 None
APOA5 rs2075291 11 116790676 HDL-cholesterol (23063622, 20686565, 22629316, 21386085)
BRAP rs3782886 12 111672685 HDL-cholesterol (21572416)
ACAD10 rs11066015 12 111730205 LDL-cholesterol (20686565)
ALDH2 rs671 12 111803962 HDL-cholesterol (21572416)
HECTD4 rs2074356 12 112207597 HDL-cholesterol (21572416, 21909109, 22751097)
rs11066280 12 112379979
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
OR4F6 rs141569282 15 101806068 None
16q13 rs247616 16 56955678 HDL-cholesterol (20686565, 19060906, 20339536, 20838585, 19060911, 20031538)
16q13 rs3764261 16 56959412 HDL-cholesterol (20686565, 23063622, 19060911, 21943158, 21347282, 18193043, 20694148, 21589926, 19802338, 19913121)
CETP rs1532624 16 56971567 HDL-cholesterol (20686565, 23063622, 22629316, 21347282, 21589926, 19060911, 20031564, 19060906, 18193044, 21943158)
ZNF77 rs146879198 19 2934109 None
LILRB2 rs73055442 19 54279838 HDL-cholesterol (20686565)

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database (https://grasp.nhlbi.nih.gov/Search.aspx) with a P-value of <1.0×10−6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr, chromosome.

Relation of genes, chromosomal loci and SNPs associated with hyper-LDL-cholesterolemia in the present study to previously examined dyslipidemia-related phenotypes.

Gene/chr locus SNP Chr Position Previously examined phenotypes
PTCH2 rs147284320 1 44828589 None
MOB3C rs139537100 1 46615006 None
PCSK9 rs151193009 1 55043912 LDL-cholesterol (23063622, 21347282, 18193044, 20686565, 22629316)
TMOD4 rs115287176 1 151170961 None
APOB rs13306206 2 21019859 LDL-cholesterol (20686565, 23202125, 23063622)
COL6A3 rs146092501 2 237371861 None
COL6A5 rs200982668 3 130470894 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
KIAA0319 rs4576240 6 24596250 None
FAM65B rs150142878 6 24847657 None
SLC17A3 rs34902660 6 25850874 Serum urate (23263486), type 1 diabetes (17554300)
ZSCAN26 rs76463649 6 28271963 None
ZSCAN31 rs6922302 6 28327533 Type 1 diabetes (17554300)
UBD rs64036 6 29559490 None
GABBR1 rs29243 6 29631325 Type 1 diabetes (17554300)
6p22.1 rs2524272 6 29714623 Type 1 diabetes (17554300)
TRIM40 rs2523995 6 30134407 Type 1 diabetes (17554300, 17632545)
DHX16 rs7749235 6 30667816 None
rs2285321 6 30670221
rs6937357 6 30672547
PPP1R18 rs9468805 6 30675932 Type 1 diabetes (17632545)
rs6457254 6 30681357
rs2394392 6 30682541
6p21.3 rs3130663 6 30698817 Type 1 diabetes (17632545, 17554300)
MDC1 rs2269702 6 30707358 Fat mass (19584900), type 1 diabetes (17554300), body mass index (19584900)
rs28986465 6 30712785
rs2075015 6 30712831
rs6924270 6 30714203
TUBB rs3132584 6 30720650 Type 1 diabetes (17554300)
rs25527 6 30723161
rs9500864 6 30725455
DPCR1 rs6933400 6 30939399 Type 1 diabetes (17554300, 17632545)
rs11970154 6 30952101
6p21.3 rs2508015 6 31042423 Type 1 diabetes (17632545), triglycerides (20686565)
CCHCR1 rs147733073 6 31145462 Triglycerides (20686565)
6p21.3 rs3130685 6 31238429 Triglycerides (20686565), type 1 diabetes (17554300)
LOC105375015 rs9264942 6 31306603 None
6p21.3 rs2596574 6 31366397 LDL-cholesterol (23063622), total cholesterol (23063622), type 1 diabetes (17554300, 17632545)
PRRC2A rs11538264 6 31635412 Type 1 diabetes (17554300, 17632545), triglycerides (20686565), total cholesterol (20686565)
LY6G6F rs9267546 6 31705659 Triglycerides (20686565)
rs17200983 6 31707506
rs9267547 6 31707724
LY6G6C rs117894946 6 31719250 Type 1 diabetes (17554300, 17632545)
MSH5 rs11754464 6 31755958 Type 1 diabetes (17554300, 17632545), triglycerides (20686565), total cholesterol (20686565)
VARS rs5030798 6 31779733 Type 1 diabetes (17632545)
rs11751198 6 31785749
HSPA1B rs6457452 6 31827773 Type 1 diabetes (17554300, 17632545)
C6orf48 rs11968400 6 31836952 Triglycerides (20686565), total cholesterol (20686565),
type 1 diabetes (17632545)
6p21.3 rs12210887 6 31847946 Type 1 diabetes (17554300, 17632545,), triglycerides (20686565), total cholesterol (20686565)
NEU1 rs13118 6 31859509 None
SLC44A4 rs117127493 6 31869232 Type 1 diabetes (17632545), triglycerides (20686565), total cholesterol (20686565)
SKIV2L rs492899 6 31965741 LDL-cholesterol (20686565), type 1 diabetes (17554300, 17632545), triglycerides (20686565), total cholesterol (20686565)
TNXB rs140770834 6 32064851 Type 1 diabetes (17554300, 17632545), triglycerides (20686565), total cholesterol (20686565)
rs11751545 6 32073266
6p21.3 rs204999 6 32142202 Type 1 diabetes (17632545)
MUC17 rs78010183 7 101035329 None
GIT2 rs2292354 12 109930396 None
HECTD4 rs11066280 12 112379979 LDL-cholesterol (21572416, 20686565), HDL-cholesterol (21572416, 21909109, 22751097)
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
ZNF77 rs146879198 19 2934109 None
APOE rs7412 19 44908822 LDL-cholesterol (23100282, 23063622, 20686565, 22629316, 19060911)
APOC1 rs445925 19 44912383 LDL-cholesterol (20686565, 21347282, 18193044, 23063622, 18193043, 20864672, 23100282)

Data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) Search database (https://grasp.nhlbi.nih.gov/Search.aspx) with a P-value of <1.0×10−6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr, chromosome.